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1. Introduction    
Tuberculosis (TB) is an ancient curse and often designated as “Captain of the Men 
of Death”. Tuberculosis has plagued human kind throughout known history. It had 
caused many major epidemics and then gradually diminished, like many other 
diseases caused by infectious etiology. Mycobacterium tuberculosis (Mtb) is one of 
the most common etiological agents causing mortality world-wide. (1).    
Genetic studies had suggested that Mtb has been present since 15,000 years. There 
is evidence of TB in human history which dates back to year 2400 to 3400 BC, 
where mummies have been shown to have evidence of TB in their spines. Due to 
the association of significant weight loss with the disease, in 460 BC Hippocrates 
named the disease as “Phithis” or “Consumption” (2).      
In 17th century the first descriptions of anatomical and pathological legends of TB 
began to arise. The high transmissibility of the disease was suspected as early as in 
the 16th century. The French army physician Jean Antoine Villemen in the year 
1865 in his land mark study demonstrated that TB can be transmitted from humans 
subjects to animal models and he also put-forth the hypothesis that a specific 
organism is responsible for the disease. In the year 1882 Robert Koch discovered a 
staining technique that led to the demonstration of the tubercle bacilli, 
M.tuberculosis (1) (2). 
Even before the discovery of the etiological agent of TB, the ancient Greeks 
pursued the search for the cure of the disease. For around 2000 years no effective 
medicine was discovered. In 1943, Selman Walksman discovered a compound 
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called streptomycin that acted against M.tuberculosis. After then a rapid succession 
of anti-TB drugs appeared in the consecutive years (2). 
For the treatment of Tuberculosis one requires to take many antibiotics over a 
prolonged period of six months or more to achieve cure. Since many years no new 
antibiotics or better anti-TB drugs have been developed. The scenario had worsened 
with the emergence of drug-resistant M. tuberculosis. Resistance in Mtb arise due to 
point mutations in the mycobacterium genome. There are two types of drug 
resistance in Tuberculosis, primary and acquired. Primary drug resistance is the one 
in which a person who has not undergone treatment acquires an infection by a 
resistant strain. Acquired resistance is the one which develops in a person during 
the course of treatment with anti-tubercular drugs (3). 
Drug susceptible tuberculosis can be cured with appropriate and regular treatment 
within 6 months. However treating drug resistant TB poses major challenge to the 
treating clinician, with only 50 -70% cure rates, despite a protracted course of 
treatment over 2 years. Other significant challenges are the cost of treatment, 
adherence to treatment and a host of different side effects (4) (5). 
Smear microscopy and conventional culture methods remains the main stay in the 
diagnosis in tuberculosis, more so in resource poor settings. However, they have 
their pitfalls. Smear microscopy has a minimal role in the detection and 
management of drug resistant tuberculosis, and conventional culture methods are 
laborious and slow as compared to the newer methods of diagnosis (6) .  
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The advent of molecular techniques has revolutionized the diagnosis of tuberculosis 
as well as the diagnosis of drug resistant tuberculosis. Many commercial tests are 
now available and also new tests are being developed. The selection of test depends 
on the clinical scenario and on laboratory aspects like the numbers of samples 
received, availability of molecular diagnostic methods and expertise (7). 
 In India, where the rates of drug resistant tuberculosis are on the rise, there is an 
urgent requirement of a rapid, low cost and robust test for the detection of drug 
resistance and, at the very least, be complementary to existing standards of 
diagnosis. Hence, there is an acute need for the further development of genotypic 
and molecular methods, and the evaluation of these methods (8).  
However there are various molecular methods with reduced turn-around time which 
includes line probe assays (LPA), GeneXpert MTB/RIF assay based on molecular 
beacons and Pyrosequencing (PSQ) assays for rapid identification of drug resistant 
TB. LPA for the rapid detection of drug resistance to Isoniazid (INH) and 
Rifampicin (RIF) and the Xpert MTB/RIF test for detection of resistance against 
Rifampicin  are the commercially available systems that are recommended by the 
World Health Organisation (WHO) for poor resource settings (7). However, there 
are no rapid molecular tests for the diagnosis of extensively drug resistant TB 
(XDR-TB) that are currently endorsed by the WHO.  
This study aims at evaluating Pyrosequencing assay for the rapid molecular 
detection of XDR-TB. The clinical isolates of M. tuberculosis from laboratory 
confirmed cases of multi drug resistant (MDR‐TB) and XDR‐TB will be studied. 
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These clinical isolates will be subjected to DNA extraction using commercially 
available DNA extraction kit. The extracted DNA will be subjected to amplification 
of the target genes by polymerase chain reaction (PCR). This will be done using 
specific primer sets for each of the genes. Each of the amplicons obtained will be 
sequenced using Pyrosequencing technology to look for point mutations which are 
known to confer drug resistance against Rifampicin and second line anti‐tubercular 
drugs. The results will be correlated with the conventional gold standard drug 
susceptibility testing.  
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2. Aim and Objectives 
Aim: 
This study aims to evaluate Pyrosequencing (PSQ) assay for the rapid detection of 
resistance to Rifampicin and Second-line drugs in Mycobacterium tuberculosis 
clinical isolates as compared to the gold standard conventional drug susceptibility 
testing. 
 
Objectives: 
i) To evaluate the validity of Pyrosequencing assay for rapid diagnosis of resistance 
to Rifampicin and Second-line drugs in Mtb clinical isolates as against conventional 
drug susceptibility testing. 
 
ii) To estimate the turnaround time as compared to drug susceptibility testing by 1% 
agar proportion method on Lowenstein Jensen media which is the current gold 
standard method. 
 
iii) To compare the performance of PSQ assay with Xpert MTB/Rif assay and Line 
probe assays (GenoTypeMTBDRplus and GenoType MTBDRsl) 
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3. Review of literature 
3.1 Epidemiology: 
3.1.1 Global Burden: 
Tuberculosis is one of the oldest known diseases affecting humans and a leading 
cause of death among millions of people each year worldwide. In the year 2014, 
there were about 96 lakh new TB cases, among which 54 lakh were males, 32 lakh 
were females and 10 lakh were children. Among the 96 lakh new TB cases, 58% 
were in the Western Pacific regions and South-East Asia and 28% in African 
regions. India (23%), China (10%), and Indonesia (10%) had the largest number of 
cases among the global total. TB deaths are around 15 lakhs (11 lakh among HIV-
negative persons and 4 lakhs among HIV-positive patients). TB ranks along side 
HIV as a major cause of death worldwide (9). 
 
 
Figure 1: Estimated TB Incidence in 2014 (9) 
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3.1.2 Drug Resistant TB: 
TB incidence rates are decreasing and improvements are being made in 
international tuberculosis control. TB mortality has been reduced by 45% 
worldwide (10). The emergence of drug-resistant tuberculosis threatens this 
progress. “Multidrug-resistant TB (MDR TB) is caused by an organism that is 
resistant to at least Isoniazid and Rifampicin, the two most potent TB drugs” (11). 
Recent World Health Organization’s  (WHO)  global estimates suggest that 20.5% 
of previously treated cases and 3.5% of new cases have multidrug-resistant 
tuberculosis (9). Rates of multidrug-resistant tuberculosis vary widely between 
countries and regions with 27 high burden countries accounting for more than 85% 
of cases. Worldwide, China, India, and Russia contribute most to the total number 
of cases. The highest proportions are found in Central Asia and Eastern Europe, 
with around 20% of new TB cases and about 50% of previously treated cases 
having multidrug-resistant tuberculosis (10). 
In the year 2006, the term “Extensively drug-resistant tuberculosis” was coined by 
Centre for Disease Control and Prevention (CDC), USA, based on WHO guidelines 
for management of drug-resistant tuberculosis (12).  
“Extensively drug resistant TB (XDR TB) is resistant to isoniazid and rifampicin, 
plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., 
amikacin, kanamycin, or capreomycin)” (13). More than 105 countries have 
reported XDR-TB has been reported by 105 countries. It is estimated that on an 
average about 9.7% of patients with MDR-TB have XDR-TB (9) (14). 
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Figure 2: By the end of 2013 Countries noted  to have at least 1 case of XDR-TB (14). 
 
3.1.3 Burden in India: 
India ranks second among the most populous countries in the world with 1/4th of the 
global new TB cases occurring in India annually (15). Among the high-burden 
countries India ranks first with 21 lakh new cases of TB every year. This 
contributes about 24% to the estimated worldwide new TB cases and 1/5th of global 
tuberculosis related mortality in the year 2013. The prevalence of MDR-TB in India 
is estimated to be low. The prevalence of MDR-TB is about 15% among 
retreatment cases and 2.2% among new cases. Among the 27 high burden MDR-TB 
countries worldwide India still ranks first despite its low prevalence probably 
because of the number of TB cases annually reported and the overall population 
size. Among the notified cases of MDR-TB globally, India contributes about 21%  
(16). Of these, 598 cases of XDR-TB have been reported from 9 different cities in 
India between the years 2000-2008 (17). 
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Figure 3: Proportion of MDR-TB diagnosed in India and initiated on treatment (15). 
3.2 Etiological agent: 
Tuberculosis is caused by a bacteria of M. tuberculosis complex (MTBC) which 
comprises 7 species and subspecies, among which Mycobacterium tuberculosis is 
the most common and important agent (18). The MTBC is formed by several 
closely related sub-species which infect human and animal populations. The 
human-adapted species, which cause tuberculosis, include M. tuberculosis, M. 
africanum, M. bovis and M. canettii. Species infecting animals include M. microti 
(voles), M. pinnipedii (seals), M. caprae (goats) and M. mungi (mongooses) and 
rarely cause human disease (19).  
M. tuberculosis complex species share 99.9% sequence identity and are likely 
evolved from a single clonal ancestor (20). 
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3.2.1 Taxonomy and Genus characteristics: 
Mycobacteria belong to 
Family Mycobacteriaceae  
Order Actinomycetales   
Genus Mycobacterium 
Genus characteristics are as follows: 
1) Acid –alcohol fastness (resists decolorisation by an acidified alcohol after 
staining with a primary stain  
2) The presence of mycolic acids which can been cleaved into fatty acid methyl 
esters by pyrolysis  
3) 61-71 % G+C content of the DNA, M.leprae being the only exception (51%) 
 
3.2.2 Morphology & Identification: 
Mycobacteria are gram positive organisms, even though mycobacterial cell wall has 
features similar to gram-positive bacteria and gram-negative bacteria (21). They are 
aerobic, nonmotile, non–spore forming, very thin, slightly curved and straight rods 
which measure around 0.2 to 0.6× 1 to 10 μm. Rarely some species may display a 
branching morphology (22) . Growth is slow because of their hydrophobic cell 
surface, the generation time being 15 to 20 hours (23), compared to bacterial 
pathogens with less than one hour of generation time, and it takes 3 to 8 weeks for 
visible growth on solid media. The organism tends to grow in parallel groups, 
thereby producing the characteristic  serpentine cording (24). 
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3.3 Structure of M.tuberculosis: 
3.3.1 Mycobacterial Cell envelope: 
Mycobacterium tuberculosis has a complex cell wall structure required for growth 
of the cell, antibiotic resistance  and virulence mechanisms (25) (26) (27) . The cell 
envelope is made up of 3 major macromolecules – “arabinogalactan, peptidoglycan 
and mycolic acids”, enclosed by a noncovalently linked capsule made up of 
polysaccharides and proteins (28). This is called the cell wall core the “mycolyl 
arabinogalactan peptidoglycan (MAGP) complex”. The high density of lipids 
creates a hydrophobhic permeability barrier in the cell wall thereby preventing 
accuracy of Gram stain. Ziehl–Neelsen stain utilizes acid fast dyes to stain the 
Mycobacteria as they are acid fast (28). The cell wall of mycobacteria is one of the 
important targets of anti-TB drugs, and various compounds that are being used in 
clinical practice for treating TB (28). 
Peptidoglycan:  
The peptidoglycan layer is surrounded by the plasma membrane and it contains 
long polymers of N acetyl muramic acid and N acetyl glucosamine, that is linked 
via peptide bridges. Instead of the traditional 4–3 crosslinks,  majority (80%) of the 
peptidoglycan layer contains the 3–3 peptide crosslinks (29) (25). It also has 
modifications, like amidation of the D-Glu and meso diaminopimelic acid residues 
of the peptide side chain and glycolylation of N acetyl muramic acid 
residues. Recognition by innate immune receptor nucleotide binding 
oligomerization domain containing 1 NOD1 is masked by amidation, but NOD2  
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can recognize glycolylated NAM thereby inducing production of inflammatory 
mediators by the macrophages infected (30). 
Arabinogalactan: 
Arabinogalactan layer surrounds the peptidoglycan layer. Galactan is a modification 
of  long arabinin polymers produced by galacto furanosyl transferases (26). 
Arabinan chain terminus are branched and modified by non-N acetylated 
galactosamine (GalN) and succinyl moieties (26). The modifications of GalN 
usually seen in mycobacteria which are pathogenic, thereby promoting active 
infection. 
Mycolic acids: 
The thick waxy lipid coat of mycobacteria is made up of long carbon chain mycolic 
acids ligated with arabinin. They contribute majorly to virulence mechanisms and 
cell wall impermeability. Mycolic acids are composed of two types of fatty acids, a 
shorter saturated α-branch (C20–C26) connecting to a meromycolate branch (C60–90). 
Mycolic acid is processed by cascade of enzymes resulting in 3 different variants 
which are methoxy-meroacids, α-meroacids and keto-meroacids. Virulence of the 
infecting Mycobacteria is determined by these three variants (31). 
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Figure 4: The Cell Envelope of Mycobacteria (31).  
 
3.4 Transmission of Tuberculosis: 
The airborne particles which carry Mtb, are called the “droplet nuclei”. They 
measure 1– 5 microns in diameter (32). When a patient having laryngeal TB or 
pulmonary TB disease coughs, shouts, sneezes, speaks, or sings there occurs 
generation of these infectious droplet nuclei. The droplet nuclei can remain 
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suspended in the air for several minutes to hours depending on the environment. It 
is not transmitted by surface contact rather it is transmitted through air (33). When a 
person inhales the droplet nuclei containing tubercle bacilli, transmission occurs,  
and it traverses oropharyngeal cavity, the upper respiratory tract, the bronchi and 
thereby reaches the alveoli of the lungs (19). 
 
3.4.1 Factors determining probability of disease transmission: 
1) Susceptibility – Immunity of the exposed individual  
2) Infectiousness is related directly to the number of tubercle bacilli that is expelled 
in the air by the patients infected with TB. Patients who expel many tubercle bacilli 
are more infectious and vice versa. 
3) Environment factors – Closed space, number of infectious droplet nuclei, poor 
aeration contributing to recirculation of droplet nuclei (34), inappropriate 
disinfection of equipment used for medical practice, improper handling of patient 
specimens etc. 
4) Duration, Frequency and Proximity of exposure – Longer duration, frequent 
exposures, close proximity lead to a higher risk of  TB transmission (33,34). 
 
3.5 Risk factors for Tuberculosis: 
The risk factors can be divided into social, environmental and biological 
determinants (35).  
The risk factors include the following: 
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a) Genetic factors – Certain genes contribute to increased risk of developing TB 
namely interferon gamma, natural resistance associated macrophage protein-1, 
Vitamin D receptor, mannan binding lectin, nitric oxide synthase 2a some Toll like 
receptors   
b) Physiological factors – pregnancy, postpartum, aging 
c) Undernutrition – Poverty, homelessness, urbanisation, overcrowding, housing 
conditions, migration, economic trends  
d) Immunological disease affecting CMI – HIV infection and AIDS  
e) Organ transplantation  
f) Malignancies – Hodgkin’s and non-Hodgkin’s lymphoma, head and neck 
carcinoma, Carcinoma of lungs, stomach and intestines 
g) Intravenous drug abuse – addiction to heroin 
h) Alcohol consumption, Tobacco smoking  
i) Silicosis 
j) Chronic disease – Chronic kidney disease, Chronic liver disease, long term 
haemodialysis.k) Iatrogenic factors - Post-gastrectomy, ureteral catheterization, 
cardiac valve homograft replacement extra-corporeal shockwave lithotripsy, 
intravesical BCG therapy for bladder cancer  
l) Drugs – long term steroid therapy, immunomodulators like anti-tumour necrosis 
factor 
m) Others – Diabetes, Connective tissue disorders, Indoor air pollution  
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Figure 5: Risk factors for TB infection and Disease (36). 
 
3.6 Pathogenesis: 
Patients with active pulmonary disease are the source of Mycobacterium 
tuberculosis (37). A person is infected when he inhales the Mtb containing droplet 
nuclei, that finally reaches the alveoli of the lungs. The alveolar macrophages ingest 
and destroy tubercle bacilli, so no actual infection occurs (33). However, at times 
Mtb will not be killed instantly, thereby developing into a small infiltrate called the 
“Primary complex” along with a draining lymph node, which is called the “Ghon’s 
focus” (38).  At this point infection is stabilised in most the cases. But few cases 
develop active disease “primary tuberculosis”, infecting the lungs or elsewhere after 
haematogenous spread of tubercle bacilli. After several months or years due to  
conditions like waning immune response, infection which was latent might get 
reactivated resulting in “post primary TB”. The disease is typically restricted to the 
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upper lobes of the lung without any evidence of infection in any other parts of the 
body (39).   
3.7 Clinical presentation: 
3.7.1 Primary Tuberculosis: 
The initial infection by the tubercle bacilli results in Primary pulmonary TB. Patient 
may be asymptomatic or may present with pleuritic chest pain and fever. The lower 
and middle lobes of the lung are most commonly. This lesion is described as 
Ghon’s focus and usually accompanied by transient paratracheal or hilar 
lymphadenopathy (Ghon’s complex). In most cases, the lesion heals spontaneously 
and becomes a calcified nodule. Few patients may develop erythema nodosum in 
the legs or phlyctenular conjunctivitis (18). 
3.7.2 Reactivation or Secondary Tuberculosis: 
It is also called as post primary (adult - type) TB or recrudescent TB. It results from 
endogenous reactivation recent infection or latent infection. It is usually localized to 
the apical and posterior segments of the upper lobes of the lung (18). Symptoms 
include malaise, low-grade fever, wasting, progressive weight loss along with night 
sweats and chills. The extensive disease results in dyspnoea, orthopnoea and 
haemoptysis (40).  
3.7.3 Extrapulmonary tuberculosis: 
The most common extrapulmonary sites involved  are the lymph nodes followed by 
pleura of the lung, bones and joints, the genitourinary tract, meninges, pericardium 
& peritoneum (18). Haematogenous dissemination of tubercle bacilli results in 
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miliary TB, more commonly seen in settings of advanced HIV infection and long-
term immunosuppression (41). 
3.8 Diagnosis of Tuberculosis: 
The current tests for the diagnosis of TB are aimed at,  
a) Early diagnosis and 
b) Drug susceptibility testing (DST) 
 
Figure 6: Laboratory diagnosis of Tuberculosis (18). ZN-Ziehl Neelsen, LJ- Lowenstein 
Jensen, DST – Drug susceptibility testing 
 
3.8.1 Smear Microscopy: 
Worldwide, the most common method used for diagnosis of TB is Sputum smear 
microscopy. The sputum specimens are examined in a microscope (42). It is the 
primary method for diagnosis of pulmonary TB  in low and middle-income 
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countries (43). It is a simple, inexpensive technique and in areas with very high 
prevalence of tuberculosis, it is very specific. (43).  
Identification of the acid-fast bacilli (AFB) by microscopy is vital due to the 
following reasons:   
a) Rapid method for diagnosing if a person has TB 
b) Identifies high risk group persons who are at increased risk of death due to the 
disease 
c) Identifies most likely transmitters of infection  
Thus, it has been an integral part of the global strategy for TB control and 
applicable widely  in different populations with varied socio-economic levels (43) 
(44) (45). It has been shown that the vast majority of cases are diagnosed by the 
analysis of two sputum samples (spot and early morning). That is, initial specimen 
was positive in 83%-87%, while 10%-12% in the second specimen. The 
examination of a third sputum sample further improves the yield by only 3-5 % 
(46). Thus, present WHO guidelines state that two sputum samples will suffice 
where work-load is very high, human resources are limited and a good external 
quality assurance system is in play (5). Further, the WHO, enforces that the 
countries which have implemented the recent policy for a two-specimen strategy 
also consider switching to a “same-day diagnosis”, mainly in countries with more 
number of defaulters, though significant organizational changes might be required 
for the maximum benefit of this strategy (47). 
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Disadvantages: 
Ziehl-Neelsen (ZN) staining has a low sensitivity of 22–43% for a single smear. 
Maximum sensitivity is up to 60% when compared with that of cultures (48). The 
threshold of detection of AFB in sputum is 104 to 105 bacilli per ml. This yield is 
often decreased due to technical and operational constraints (49). The sensitivity is 
even lower in paediatric and AIDS patients who usually present a pauci bacillary 
picture usually. (50) (51).  
To overcome the above-mentioned disadvantages of conventional light microscope, 
“Light-Emitting Diode fluorescence microscope” (LED-FM) was introduced in 
1930. It uses an auramine-rhodamine or auramine O dye (acid-fast fluorochrome), 
weaker acid as a decoloriser , and a counter stain with a quencher such as potassium 
permanganate (52). The fluorochrome staining is simple as compared to ZN 
staining (53). Fluorescence Microscopy was recommended by the WHO for 
detection of AFB in countries with high TB burden. LEDs are inexpensive 
relatively, can be powered using batteries and mains, with thousands of hours as 
effective lifespan (54). It’s sensitivity is 8–10% higher than ZN staining and 
specificity similar to ZN staining (55). The increased sensitivity is attributed to the 
following reasons: 
 i) The absorbable nature of mycolic acid for carbol-auramine is stronger than for 
carbol-fuchsin, thus large number of AFB’s can be stained with FM in comparison  
to ZN (56).  
ii) Under high power field, larger field areas can be examined in FM as compared to 
by ZN which uses oil immersion fields (OIF) 
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iii) Fine contrast between the background and the bacilli, thus enables identification 
easier (55). 
The shortcomings of FM is that the fluorochrome dyes are incorporated by 
inorganic objects resulting in a possibility of false-positive results (53). It cannot 
replace culture when it comes to the diagnosis of drug resistance (42). 
3.8.2 Culture methods: 
Definitive diagnosis is based on identification and isolation of Mtb from the clinical 
specimens (18). Cultures require only 10 to 100 organisms to detect Mtb thus, the 
sensitivity is 80% to 93% and specificity is as high as 98%. The sensitivity for the 
diagnosis of M. tuberculosis is increased by cultures and it also allows drug-
susceptibility testing, speciation, and genotyping for epidemiologic purposes if 
needed (57). M. tuberculosis, grows slowly in solid media. It takes around 4–8 
weeks for visible growth to be detected. Over the last decades, many new 
methodologies for diagnosis have been introduced, involving liquid culture, which 
are faster, with the turnaround time of 10 days though they run the risk of 
contamination. 
a) Solid media: 
Egg-based media: 
The “Lowenstein-Jensen (LJ) media” is the most commonly used medium. It 
contains whole egg yolk or whole egg, salts, potato flour and glycerol. It is 
solidified by inspissation. The characteristics of the media are its good buffering 
capacity, several months of long shelf life if refrigerated, and supporting good 
growth of most mycobacteria. Disadvantages of this media are depending on the 
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quality of the eggs used there can be batch to batch variability, difficulties in 
discerning colonies from debris, and the inability to achieve consistent and accurate 
drug concentrations for susceptibility testing (58). 
Agar-based media: 
The Synthetic Middle brook media -7H10 and 7H11 are the most commonly used 
agar based media. Compared to egg-containing media, agar-based media are better 
defined chemically. They do not readily support the growth of contaminants, 
however, the plates are expensive to prepare and their shelf life is relatively short (1 
month in the refrigerator).  Agar-based media are transparent and provide a ready 
means of detecting the early growth of microscopic colonies and can be easily 
distinguished from inoculum debris (58).  
b) Liquid media: 
Cultures based on liquid media yield significantly more rapid results (around 8 to 
10 days) than solid-medium-based cultures. The rate of isolation for mycobacteria 
are higher. Middle brook 7H9 and Dubos Tween-albumin broths are commonly 
used liquid media for both sub culturing stock strains of mycobacteria and 
preparing the inoculum for drug susceptibility tests and other in vitro tests (58). 
Currently, for the isolation of mycobacteria, commercially available culture systems 
in the market ranges from simple tubes, like the MGIT (Becton, Dickinson 
Microbiology Systems), to the fully automated systems  like Bactec MGIT 960 
(Becton, Dickinson), VersaTREK culture system II (Trek Diagnostic Systems, 
Cleveland) or the ESP culture system II and MB/BacT Alert 3D system 
(bioMérieux) (58). These nonradiometric techniques have been tested in various 
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studies which showed good concordance against solid media and the radiometric 
Bactec 460 technique, which was for long considered the gold standard but no 
longer used now because of concerns of handling radiolabelled products, its 
disposal and cost (59)(60). 
3.9 Drug susceptibility testing (DST): 
3.9.1 Need for DST: 
Effective TB control mainly aims at preventing drug resistant TB resulting from 
multifactorial causes like patient-related factors, health care provider, health-care 
facility. Poor quality and irregular supply of drugs, errors while prescribing the 
drugs and poor adherence to treatment  are known to contribute to drug resistance 
of Mtb. Definitive diagnosis of MDR-TB and XDR-TB requires Mtb  isolation and 
identifion followed by a drug-susceptibility testing (DST) using either a solid or 
liquid media or by doing a molecular test approved by the WHO for the detection of 
Mtb DNA and resistance conferring mutations. (61). 
With increasing incidence of drug resistant tuberculosis, the need for a reliable DST 
report also increases following which an appropriate treatment regimen can be 
initiated to the patient. There occurs selective multiplication of resistant mutants 
within the lesions due to inadequate or improper treatment leading to drug 
resistance. The resistance level of these mutants and its frequency of occurrence 
vary depending on the sites of action of the drug and the mutated genes (62). 
 
3.9.2 Methods for Drug susceptibility testing: 
The techniques available for DST can be divided as follows 
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Phenotypic methods: 
Phenotypic DST involves culturing the Mtb  in the presence of anti-TB antibiotics 
to detect the presence of growth (indicates resistance to the drug) or inhibition of 
growth (indicates susceptibility to the drug). 
Genotypic methods: 
Genotypic method target unique molecular mutations that can identify resistance of 
Mtb to anti-TB drugs (63). 
 
Figure 7: Current Laboratory methods for diagnosis of drug resistant TB (61). MODS – 
Microscopically Observed Drug Susceptibility, NGS – Next Generation Sequencing 
Drug 
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3.10 Phenotypic methods: 
Phenotypic methods can be performed either directly or indirectly, on a solid or 
liquid media.  
a) Direct testing:  
In direct testing the concentrated specimen is inoculated directly in a medium which 
is drug-free and and in a medium with drugs. This test is performed only on those 
specimens that contain adequate numbers (at least one bacillus in ten HPF)  of acid-
fast bacilli in direct smear examination, because the results may not be reliable 
when there is scanty growth in culture. 
 Direct sensitivity testing is not performed in many laboratories, because it is not 
practical as a routine to examine smears before inoculation of the culture medium 
and, direct sensitivity tests are not as reliable as the indirect methods. When  the 
direct smear examination is negative or scanty, indirect sensitivity testing may be 
required (64).  
b) Indirect testing: 
This method involves inoculation of a pure culture grown from the original 
specimen in a drug-containing medium. Indirect sensitivity testing is usually used 
on smear-negative samples or if the direct test results are invalid in case of the 
drug-free quadrants with insufficient numbers of colonies, contamination or poor 
growth following three weeks incubation (58). Indirect phenotypic testing methods 
have been extensively validated and are considered as the current gold standard 
method. The commonly used methods for solid media are the resistance ratio 
methods, absolute concentration and the proportion method for solid media and the 
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proportion method for liquid culture systems. The results obtained with the three 
methods have shown good concordance to DST for first-line anti-tubercular drugs 
(63).  
3.10.1 Solid culture based methods: 
a) Absolute concentration method: 
The method employs an inoculum which is standardized, and tested by growing it  
in media with drugs with graded concentration and in media without drugs. 
Different concentrations of each drug are tested and resistance is expressed in terms 
of minimum inhibitory concentration (MIC) (65). The MIC is defined as “the 
lowest concentration of anti-TB drugs that inhibits more than 99% of the growth of 
the mycobacterial culture”. The MIC is estimated by comparing the control well 
with growth. The MIC interpretation, is mainly based on breakpoint concentrations 
for each drug. The reading is interpreted as susceptible if growth occurs at the 
breakpoint concentration, and interpreted as resistant if growth occurs at higher 
concentration of the drug (66). Satisfactory results can be obtained only when the 
inoculum employed is adequately standardized, the critical concentration of the 
drug should also be standardized for the laboratory and for the reference method to 
an adequate sample of wild strains (64). 
The disadvantage of this method is that it is a phenotypic based method 
which involves the actual growth of slow growing mycobacteria as an indicator of 
resistance (66). The viability of organisms may also affect this method (65).  
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b) Resistance ratio method: 
This method involves the comparison of the growth of unknown strains of tubercle 
bacilli with the standard laboratory reference strain (H37Rv). Media with two- fold 
dilutions of the drug in parallel are inoculated with the standard reference strains 
H37Rv. Resistance is calculated as “the ratio of the MIC of the test strain to the 
MIC of the reference strain in the same set” (65). The test strain is interpreted as 
resistant if growth occurs on the media containing a given drug, in a given 
concentration in which control strain is susceptible (67). 
The disadvantage of this method is that it is greatly affected by the inoculum size 
and the strain viability and variations in susceptibility of the reference strain tested 
may affect the resistance ratio of test strain (65). 
c) Agar proportion method: 
It employs the following principle - Every wild strain of tubercle bacilli contains 
some mutants resistant to antibacterial drugs. The difference between a resistant 
strain and a susceptible strain is that the proportion of bacteria that is resistant 
among the entire number of bacteria making up the strain is much higher in a 
resistant strain than in a susceptible one (64). 
It uses the seeding of drug-free (control quadrant) and solid media containing drugs 
with equal quantities of two dilutions of a standardized inoculum. To compare the 
growths on different media accurately, care must be taken to ensure that a 
suspension of cells is homogeneous. For the test to be valid, at least one of the 
dilutions on drug-free media should have isolated countable colonies (50-100 
colonies) by 3 weeks (68). If there are less than 50 colonies it indicates insufficient 
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growth, and the test is invalid and it should be repeated. In this method, the percent 
resistance is obtained by dividing the colony count on the drug containing media by 
the colony count on the drug-free media. When the percent resistance is greater than 
1%, the strain is considered to be resistant to the drug (58). The proportion method 
is current phenotypic solid culture based method of choice for detecting drug 
resistance in MTBC (65) . 
3.10.2 Liquid culture based methods: 
a) BACTEC 460TB system:   
In the developed nations, the radiometric, semi-automated BACTEC 460 TB 
system (Becton Dickinson, Sparks, MD, USA) is accepted as the reference 
standard. The growth of mycobacteria occurs in BACTEC 12B medium which 
contains Middle brook 7H12 broth along with PANTA (Amphotericin B, 
Azlocillin, Nalidixic acid and Polymyxin B and Trimethoprim) and palmitic acid 
that is C14 labeled. The detection of mycobacterial growth is carried out by 
measuring 14CO 2 quantitatively, produced by the metabolism of  C14-labelled 
palmitic acid in the medium and reported as “Growth index” (GI). It gives culture 
and DST results in 10-14 days, but in India there are only 37 installations of 
BACTEC 460 TB system, suggesting that it’s not commonly used in India (59). 
The major disadvantage of this system is the production of radioactive waste, and 
the consequent dilemma of radioactive waste disposal. Another drawback is the 
cumbersome handling of vials during re-incubation (59) (60). This system is no 
longer available commercially (58). 
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b) MB/BacT System: 
MB/BacT ALERT 3D system (Organon Teknika Corp. Boxtel, Netherlands), is a 
continuously monitored closed nonradiometric fully automated system with a 
computerized database management. This method employs a middle brook 7H9 
medium, growth factors and antimicrobials, MAS (Amphotericin B, Azlocillin, 
Nalidixic acid and Polymyxin B and Trimethoprim). At the base of each culture 
vial there is a gas-permeable sensor with colorimetric indicator which changes 
colour from green to yellow when CO2 is produced actively growing mycobacteria. 
Every compartment of the instrument where the incubated vials are kept has a 
reflectometer and a detection unit. Every 10 minutes the values measured are 
transferred to a computer, which indicates vials with growth of  mycobacteria based 
on an algorithm (69). It detects resistance to Rifampicin, Isoniazid, Streptomycin, 
Pyrazinamide and Ethambutol. It’s performance parameters are good with the 
sensitivity of 100%, and time to detection of susceptibility is 7 days (70). 
The benefits of this system over the BACTEC system are it provides a high level of 
automation, with decreased risk of vial inversion or transcription errors. It is a 
closed system with no cross-contamination risk after specimen inoculation. There is 
no radioactive waste disposal issues and it has data management capabilities. The 
maintenance cost is low. For the culture of mycobacteria in liquid media the 
MB/BacT system can be used as an alternative to other radiometric systems. 
Disadvantages include high rates of contamination and more time for detection (69) 
(60). This system has also been withdrawn for performing DST (71). 
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c) The MGIT 960 System: 
The “Mycobacteria growth indicator tube (MGIT 960, Becton Dickinson, USA)” 
introduced in 1995 for the growth and detection of mycobacteria from clinical 
specimens. The MGIT tube contains modified Middle brook 7H9 broth, with 
OADC (oleic acid, albumin, dextrose and catalase) and a PANTA (polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim, azlocillin) antibiotic concoction and 
the bottom of the tube contains a silicon rubber which is impregnated with 
ruthenium pentahydrate (fluorescence-quenching-based oxygen sensor).When 
actively growing organisms utilize the dissolved oxygen, the reduced oxygen 
concentration enables the generation of fluorescence, which is then measured and 
expressed as growth units (GU). It is a fully automated system, monitoring the 
growth of microorganisms continuously every hour through fluorescence detection. 
The system uses a nonradiometric medium and does not require the use of needles 
for addition of growth supplement or inoculation of organisms. The time to 
detection was around 13.3 days. The drugs are used in slightly lower concentrations 
than that used in proportion method which brings down the possibility of false 
susceptibility results (58). 
This system was approved by the FDA since the year 2002 for susceptibility testing 
of MTBC to Streptomycin, Isoniazid, Rifampicin, and Ethambutol (SIRE) and 
Pyrazinamide. The susceptibility testing to second line drugs in a multicentre study, 
for Amikacin, Capreomycin, Ethionamide, Prothionamide, Ofloxacin, Linezolid 
and Rifabutin was shown to be reliable and reproducible (72). 
32 
 
The inconveniences in using this system are, the user has to make the working 
solutions of the drugs, resistance or susceptibility is not automatically defined by 
the instrument, as is the case of primary drugs, and based on the GU values 
retrieved from the instrument results have to be analysed manually. Growth 
detection failures are also seen with this system (73) (72). 
d) Versa TREK: 
This was formerly called “ESP II Culture system”. It is also a fully automated 
system, monitoring for growth and detection of mycobacteria continuously, this 
system is also approved by FDA for susceptibility of MTBC to all primary drugs. 
The medium consists of a Middle brook 7H9 broth, which has been enriched with 
growth supplement (casitone and glycerol), and contains cellulose sponges as a 
growth support matrix that increases the surface area for exposure to oxygen. 
Oxygen consumption due to microbial growth leads to pressure changes within the 
headspace above the broth medium in a sealed bottle. This technology is based on 
the above principle. It has a special detection algorithm for detecting slowly 
growing mycobacteria (58) (60). 
The advantages of Versa TREK include, it is less labour-intensive, the data 
management is simple for tracking of results and no cross-contamination risks (71) 
(74). 
3.10.3 Non-commercial Rapid phenotypic methods: 
The following are the rapid, non-commercial phenotypic culture methods which 
have been specifically used in resource limited settings.  
Microscopic observation of drug susceptibility (MODS),  
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Colorimetric redox indicator (CRI) method  
Thin-layer agar method 
The nitrate reductase assay (NRA) and  
Mycobacteriophage-based assays (75) (68). 
The WHO endorsed methods are MODS, CRI and NRA. For direct testing of 
sputum specimens NRA and MODS are recommended. It is also recommended for 
indirect DST of Mtb isolates grown in culture along with CRI method. But the 
above methods cannot detect XDR-TB. Thus the diagnosis of XDR-TB still relies 
on conventional culture and DST (75). 
a) Microscopically observed drug susceptibility (MODS): 
This system is a liquid culture-based DST method. It employs the following 
principles, the growth of Mtb is fast in liquid culture medium compared to a solid 
medium. At an early stage (7 days), the characteristic cord formation can be 
visualized in a microscope from the liquid medium and by incorporating drugs into 
the medium it permits rapid and direct DST along with the bacterial growth 
detection (76).  
The MODS method does not require the use of any proprietary culture media. It 
employs Middle brook 7H9 broth medium, supplemented with OADC and a 
selective antibiotic/ antifungal cocktail. It uses a 24-well microtiter plate.12 wells 
are used for each specimen, including 4 control wells with no antituberculous drug 
and 8 drug-containing wells including low and high concentrations of INH, RIF, 
EMB, and STR. The 24-well microtiter plate should be sealed in plastic bags and 
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the microscopic observations are made without opening them. MODS results are 
read by examining each well with an inverted microscope (77).  
Growth of MTBC is indicated by the presence of cording clumps. The method 
enables rapid detection of growth and provides a quick indication of susceptibility 
or resistance to the primary drugs. The percentage agreement for susceptibility 
testing between MODS and the reference standard is 97%, 100%, 95%, 97%  for 
isoniazid, rifampin, ethambutol, streptomycin respectively (92%) (78). 
The benefits of MODS include the lack of any proprietary ingredient and its rapid 
and accurate detection of M.tuberculosis along with detection of MDR-TB. This 
method is cost effective in resource limited settings with high TB burden (77) (78). 
The drawbacks are the MODS method entails some requirements that may be 
difficult to achieve in limited-resource settings like acquiring and storing labile 
ingredients such as OADC. It also requires the sophisticated equipment and 
facilities, like a biological safety cabinet, high-speed centrifuge, incubator, inverted 
microscope etc., and safety practices of a biosafety level 3 laboratory (58). 
b) Colorimetric Redox Indicator: 
Colorimetric method works on the following principle Reduction of a coloured 
indicator added to the culture medium after Mtb has been exposed in vitro to 
different antibiotics.  Resistance to a particular drug is detected by reduction of the 
dye from blue to pink colour (Alamar blue dye), due to oxidation-reduction 
mechanism of viable organisms, which is directly proportional to the viable number 
of  mycobacteria in the medium. The indicators evaluated have given comparable 
results in comparison with the gold standard proportional method. The various 
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indicators used are the tetrazolium salts, the redox indicators resazurin and alamar 
blue. For isoniazid and rifampicin studies have shown sensitivity and specificity 
ranging between 89% to 100%. (79) (80). 
c) Nitrate reductase assay (Griess method):  
M.tuberculosis reduces nitrate to nitrite. Incorporation into the LJ medium of 
Griess’ reagent detects this reaction and produces a coloured product, which 
determines if the organism is susceptible or resistant. Susceptible organisms, in the 
presence of antibiotics, are unable to carry out the reduction of nitrate to nitrite, 
whereas resistant organisms can and produce a red-pink colour of the medium. It 
can be carried out both on clinical samples and on culture isolates. The average 
time for results is around 18 to 28 days. For the detection of INH resistance the 
sensitivity and specificity was 94% and 100% respectively and for RIF resistance, 
the sensitivity and specificity was 99% and 100% respectively. However, the Griess 
reagent kills the organisms when added to the tubes, so if further testing is needed 
multiple tubes are needed to be inoculated. In addition, nitrate-negative AFB does 
not exclude MTBC, because not all members of the MTBC reduce nitrate, thus 
requiring further testing (68) (81). 
Rapid phenotypic methods – Limitations: 
Limitations include the lack of reliable conventional breakpoints for interpretation, 
reduced accuracy in mixed mycobacterial cultures, reduced fitness, growth of other 
mutant organisms requiring higher inoculum to increase the sensitivity of the test 
(82). 
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3.10.4 The need for rapid testing in drug resistant TB: 
Improved TB control mainly relies on early diagnosis of drug resistance and early 
institution of proper treatment regimen. Globally due to the increasing incidence of 
MDR-TB and XDR-TB there is an urgent need for rapid methods of DST in Mtb. 
The national TB control programmes are aimed at preventing the spread of drug-
resistant TB and treating the patients diagnosed as MDR and XDR-TB. Due to the 
lack of appropriate diagnostic methods and deficiencies in the laboratory capacities 
there occurs hurdles in achieving the above aims (63) (61). 
A rapid and reliable diagnosis is essential for treating drug-resistant TB. The DST 
tests are therefore crucial. M.tuberculosis bacteria grow slowly - the agar proportion 
method requires six to eight weeks to give results, while the liquid culture methods 
gives results in four to five weeks. Molecular methods can cut down the turn-
around time for resistance testing to a few days. This reduces periods of 
infectiousness of TB cases by at least a month, reducing the further spread of the 
disease to both the community and the health care worker, and better treatment 
results for the patient with far less morbidity and mortality (5) (61). 
The benefits of molecular techniques in the detection of drug resistance are that 
they are robust, rapid, has high throughput, with lesser technical skills and 
manipulations as compared to the gold standard conventional culture and DST. 
These molecular methodologies require only simple-to-use equipment which serve 
as a platform for testing clinical samples for various other diseases also. 
Additionally, specimen transport conditions does not impact the outcome of the 
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molecular tests since they does not require viable bacteria for the purpose of 
diagnosis (68).  
3.11 Genotypic methods: 
Real-time PCR coupled to fluorescence detection by molecular beacons or other 
probes has been used for detecting INH resistance in MTBC. Various molecular 
methods like Sanger sequencing, Pyrosequencing and Next-generation sequencing, 
is also being designed for detecting resistance to INH, RIF, EMB, PZA, FQ, and 
SLI. 
Xpert MTB/RIF and Molecular LPA (Line Probe Assays) are presently the two 
molecular methods endorsed by WHO for the detection of drug resistance in MTBC 
genotypically. These methods have shortened the time to diagnosis of MDR-TB by 
detecting INH and RIF resistance. This aids in screening of patients at risk of 
MDR-TB, identifying patients on inappropriate or inadequate first-line anti-TB 
regimens, thus interrupting the transmission of MDR-TB. Molecular methods like 
Hain MTBDRsl assays, Pyrosequencing assays have also been widely used for 
detection of Second-line drug resistance and XDR-TB (63) (58). 
Molecular methods are divided into two major categories, which are probe-based 
methods and sequence-based methods.  
Probe-based methods: 
Cepheid’s GeneXpert MTB/RIF assay using molecular beacon probes, and INNO-
LiPA Rif.TB, Hains’s MTBDR, Hain’s MTBDRplus and Hain’s MTBDRsl assays 
using line probes are probe based methods. 
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Sequence-based methods:  
Sanger sequencing, Pyrosequencing and Next-Generation Sequencing are sequence-
based methods.  
Probe-based methods detect the presence or absence of mutations, while sequence 
based methods provide the exact sequences of either wild-type organisms or 
mutants. Since all mutations are not always associated with drug resistance, when a 
mutation is detected by probe-based methods without providing the identity of the 
mutation, it should be confirmed by a sequence-based method. Revealing the 
identity of a mutation allows discerning the association of the mutation with drug 
resistance (58). 
 
3.11.1 Probe based methods: 
a) Xpert MTB/Rif (Cepheid, Sunnyvale, USA): 
This is a self-sufficient, automated system that can be deployed with basic skills. 
Decontamination and concentration (using sodium hydroxide and isopropranol) is 
performed in 15 minutes. The cartridge-based system incorporates an extraction 
method where the DNA is captured on a filter, washed and lysed via sonication. It 
is a fully automated hemi nested real time PCR assay using 6 molecular beacons 
(five of which are for the rpoB gene and the last is an internal control). Detection 
and quantitation of the targeted nucleic acid sequence is done in approximately 1 
hour 45 minutes. Rifampicin resistance is detected easily because 95% of all 
Rifampicin-resistant M.tuberculosis strains contain mutations localised within the 
81 bp core region of the bacterial RNA polymerase β subunit (rpoB) gene, which 
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codes for the active site of the enzyme. These are highly suggestive of Rifampicin 
resistance. On either side of this region are M.tuberculosis complex-specific DNA 
sequences. Thus, M tuberculosis and Rifampicin resistance can be tested 
concurrently by targeting one amplicon generated with PCR technology. Moreover, 
Rifampicin resistance is strongly indicative of MDR-TB.  
 
 
 
Figure 8: Steps of Xpert MTB/Rif Assay (83). 
 
It has an analytical sensitivity of 5 genome copies of purified DNA with the limit of 
detection 131 CFU/ml (84) (83), which is much lower than that of smear 
microscopy (10000 CFU/ml), is similar to solid culture, but is not quite as sensitive 
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as liquid culture (10 CFU/ml). Studies have shown that the assay poses a minimal 
biohazard risk and given adequate room ventilation, might be done without the need 
for a biosafety hood. In sputum positive cases it has high sensitivity ranging from 
98%-100% and a high specificity ranging from 97-100%. Rifampicin resistance 
was detected with 95.1% sensitivity and 98.4% specificity. For detecting extra 
pulmonary TB the sensitivity and specificity was 86% and 100% respectively (85) 
(84) (68).  
There are few issues restricting the performance of the Xpert MTB/Rif assay at 
small health care settings. Even though certain centres successfully tested battery 
operation, this device requires stable electricity supply. Device deployment above 
30°C is not recommended currently by the manufacturer and cartridges are stable at 
temperature 2–28°C. The Gene Xpert device also needs to be calibrated yearly. It 
also has a  low sensitivity in smear negative tuberculosis ranging from 72-75%, the 
high cost of cartridge and reagents, and its inability to detect mutations outside the 
pre-specified target region and inability to detect Isoniazid mono resistance (84) 
(68). 
 
b) Line probe assays: 
The line probe assays are a family of DNA strip tests that uses nucleic acid 
amplification and reverse hybridization techniques for the rapid detection of drug 
resistant tuberculosis (70). It is based on the hybridization of labeled amplicons to 
oligonucleotide probes that have been immobilized on a membrane strip (71). 
These assays, though not as rapid or as cheap as the Xpert (MTB Rif), have the 
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advantage of detecting resistance to second line drugs. A meta-analysis for the 
Genotype MTBDR has shown a high sensitivity and specificity for Rifampicin 
resistance -98.1% and 98.7% respectively. The sensitivity for Isoniazid resistance 
was 84.3% while specificity was 99.5% .The meta-analysis also showed an 
improved sensitivity for the detection of Isoniazid resistance-90%, when it was 
performed with the newer Genotype MTBDRplus assay, which also detects Inh A 
mediated resistance (72). A second version of the Genotype MTBDRplus assay has 
been introduced, which is an improvement over the first version for extrapulmonary 
samples. A line probe assay for the diagnosis of XDR-TB (Hain’s Genotype 
MTBDRsl kit) has also been introduced which picks up resistance to Ethambutol, 
Aminoglycosides and Fluoroquinolones. The latter test, however has not yet been 
endorsed by the WHO for testing clinical specimens. Although the line probe 
assays have several advantages, they cannot be read in isolation and their use does 
not preclude the need for culture. 
 
Figure 9: Procedure of Line Probe Assay (86). 
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Draw backs of LPA: 
Line probe assays are complex and requires biosafety cabinets. LPA is suitable only 
for regional and national level laboratories. It requires at least three separate rooms, 
dedicated equipment, reagents and consumables to decrease DNA cross-
contamination. WHO recommends LPA to detect resistance to INH and RIF only 
on specimens which are smear-positive and isolates of Mtb.  LPA is used in the 
diagnosis of MDR-TB but conventional phenotypic culture methods (solid or 
liquid) is required in monitoring treatment response for MDR-TB patients (culture 
conversion). To detect XDR-TB conventional second-line DST is required because 
WHO has not currently recommended the use of LPA for diagnosis of resistance to 
second-line drugs due to sub-optimal performance of the test on clinical specimens 
(87) (68). 
The major problem is the interpretation and readings of different LPA patterns even 
for a technically skilled laboratory personnel. There can be patterns in LPA which 
may represent silent mutations (no change in amino acid) and may be susceptible 
by phenotypic methods. These molecular assays lack the capacity to detect lower 
levels of resistant organisms in a heteroresistant population (mixed wild-type and 
mutant) which limits the use of LPA for the early detection of drug resistance. The 
LPA does not have the ability to differentiate between a high level and low level 
resistance mutations which may guide the clinicians either to increase the dose of a 
particular drug or discontinue the drug (68). 
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3.11.2 Sequence based methods: 
a) DNA Sequencing (Sanger’s): 
The DNA fragments are sequenced by “chain-termination method” in Sangers 
sequencing. It is considered as the gold standard DNA sequencing method. Here, 
the primer specifically binds to the single stranded DNA template. DNA 
polymerase initiates DNA extension which begins at the site of primer binding. 
DNA extension is then terminated eventually due to a dye-labelled 
dideoxynucleotide (ddNTP) which interrupts the bond between the two subsequent 
nucleotides (phosphodiesterase bond). This results in DNA fragments of varied 
lengths. The DNA fragments are separated by electrophoresis and sequenced later. 
It remains the gold-standard of DNA sequencing. It’s very accurate, and it can read 
larger amounts of DNA. Due to the lack of time, expertise, and cost Sanger’s 
sequencing is not been used routinely in commercial settings for detecting drug 
resistance in Mtb. It is only used for research purposes (82). 
 
b) Pyrosequencing:  
Pyrosequencing (PSQ) is a novel rapid DNA sequencing technology, which was 
first developed as an alternative to conventional Sanger sequencing for de novo 
DNA sequencing. 
Principle: 
PSQ technique is based on “sequencing by-synthesis” principle. The method detects 
the released pyrophosphate (PPi) formed during DNA synthesis. During DNA 
synthesis, it uses four enzymes series for the detection of nucleic acid sequences. In 
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PSQ assay the sequencing primer gets hybridized to a single-stranded biotin-
labelled DNA template followed by reaction with the four enzymes – DNA 
polymerase, Luciferase, ATP sulfurylase and Apyrase. The reaction utilizes the 
following substrates – Adenosine 5′ Phosphosulfate (APS) and Luciferin. The 
reaction mixture is added with four deoxynucleotide triphosphates (dNTPs) 
seperately. Due to nucleotide incorporation by the polymerase enzyme, PPi is 
released, proportional to the amount of incorporated nucleotide. The PPi is 
converted quantitatively by ATP sulfurylase to Adenosine Triphosphate in the 
presence of APS. The Adenosine Triphosphate (ATP) initiates the conversion of 
luciferin to oxyluciferin in the presence luciferase. Thus visible light is produced 
which is directly proportional to quantity of ATPs produced. Apyrase (enzyme 
degrading nucleotides) degrade the ATPs continuously and the non-incorporated 
dNTPs in the reaction mixture. The sequence of the template DNA can be 
determined since the added nucleotide is known. The generated light can be seen as 
a signal peak in the pyrogram which is directly proportional to the quantity of 
incorporated nucleotides. (88).  
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Figure 10: Schematic representation of Pyrosequencing (88). 
 
Similar to Sanger sequencing, PSQ also provides exact DNA sequences, thus 
detecting both novel and previously known mutations. In case of discrepant results 
where phenotypic and genotypic results doesn’t correlate PSQ can be used to 
resolve the issue. It can also discriminate between a low and high level resistance 
mutation thereby guiding the clinician in therapy. 
Advantages: 
It’s is an up-coming latest tool for the rapid identification of Mtb in both growth-
positive cultures and smear-positive sputum specimens. The sequencing assays can 
be identified and reported within 1 to 3 days using automated sequencers and well 
trained staffs. Other advantages include simplicity of processing, speed, reduced 
cost, ease of interpretability, and relative high throughput (82) (68). For testing 
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clinical isolates sensitivity of the assay was 94% for INH, 96% for RIF, 93% for 
FQ, 84% for AMK, 88% for CAP, and 68% for KAN. The specificities of the assay 
were 100% for RIF, FQ, AMK, and KAN, 96% for Isoniazid and 97% for 
Capreomycin. With regard to performance in testing clinical specimens, the PSQ 
assay yielded a sensitivity of 98.4%  and specificity of 95.8% for all sub assays (89) 
(90).  
Disadvantages: 
A major drawback of Pyrosequencing is that, currently the technique is limited to 
analysis of short DNA sequence (< 50 nucleotides). The mutations which are 
located outside the target gene of interest cannot be detected by this assay. The 
maintenance, installation, and cost limits it’s use in poor resource settings (88) (68). 
 
c) Next-Generation sequencing (NGS) 
NGS is referred as “Massive-parallel DNA sequencing”, “Deep sequencing” or 
“Second-generation sequencing” because of  the high-throughput DNA sequencing 
technology which is capable of sequencing large numbers of different DNA 
sequences in a single reaction (in parallel). Basic work flow of NGS includes four 
phases that is sample collection, template generation, sequencing reactions and 
detection, and data analysis. In contrast to Sanger sequencing, the sequencing speed 
and the DNA sequence data generated with NGS are exponentially greater, and are 
produced at significantly reduced costs (91).   
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4. Materials and methods 
4.1 Study design: 
This was a prospective study for a period of 1 year, 10 months done on clinical 
isolates of Mycobacterium tuberculosis obtained from patients with Tuberculosis, 
for detection of mutations in rpoB (RIF), gyrA (FQ), rrs and eis promoter 
(CAP,KAN) genes by PSQ and the PSQ results were correlated with the 
conventional gold standard drug susceptibility testing results. 
4.2 Ethics approval: 
The approval for the study was obtained from the Institutional Review Board, 
Christian Medical College, Vellore (IRB Min. No. 9131 dated 12.11.2014).  
4.3 Study Duration: 
The study was conducted over a period of 1year, 10 months from November 2014 
to August 2016.  
4.4 Study samples: 
The study samples comprised of clinical isolates of MDR TB/XDR TB and 
susceptible MTB isolates. The samples were received in the Microbiology 
laboratory as part of routine diagnostics for culture and routine mycobacterial drug 
resistance testing. 
4.5 Sample size calculation: 
The sample size was determined based on the prevalence of MDR‐ TB and XDR‐
TB in the community and sensitivity and specificity of the experimental test. 
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Consecutive culture isolates which were resistant and sensitive were selected and 
were evaluated by Pyrosequencing assay. 
Number of samples to be evaluated ‐ 50 (40MDR/XDR TB isolates, 10 susceptible 
isolates)  
Based on the formula 4pq/d2 + 4p1q1/d2 (Where p=sensitivity, q =100‐sensitivity, 
p1=specificity, q1=100‐specificity and d =10%) 
4.6 Inclusion criteria: 
1. Clinical isolates which were found to be MDR TB/XDR TB  by the gold 
standard agar proportion method of mycobacterial drug susceptibility testing. 
2. Clinical isolates which were found to be susceptible TB by the gold standard agar 
proportion method of mycobacterial drug susceptibility testing. 
4.7 Exclusion criteria:  
1. Clinical isolates of those samples which were not requested for mycobacterial 
drug susceptibility testing.  
2. Clinical isolates with no growth on the LJ medium used for mycobacterial drug 
susceptibility testing. 
3. Clinical isolates which fail Pyrosequencing assay while performing the run. 
4.8 Data source  
Relevant information about the clinical isolates of the patient samples were 
obtained from the Clinical Work Station and clinical records. Testing of the clinical 
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Figure 11: Detailed Study Algorithm 
isolates were undertaken in the Department of Clinical Microbiology and 
Department of General Pathology. 
4.9 Study algorithm: 
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4.10 The Reference Test: 
4.10.1. 1% Agar Proportion method: 
This method enables precise estimation of the proportion of mutants resistant to a 
given drug. Ten-fold dilution of inoculums were plated in both control and drug 
containing media, at least one dilution should yield isolated countable colonies (50‐
100 colonies). When these numbers were corrected by multiplying by the dilution 
of inoculums used, the total number of viable colonies observed on the control 
medium and the number of mutant colonies resistant to drug concentration tested 
may be determined. Only one concentration per drug is used: 
Streptomycin (STM): 4 μg/ml 
Isoniazid (INH): 0.2μg/ml 
Rifampicin (RIF): 40μg/ml 
Ethambutol (ETM): 2 μg/ml 
Capreomycin (KAP): 40μg/ml 
Ofloxacin (OLOX): 2μg/ml 
Kanamycin (KAN): 30μg/ml 
Ethionamide (ETH): 40 μg/ml 
 
The suspension (4mg moist weight of representative sample of bacterial mass) was 
visualized as 2/3 loopful of 3mm internal diameter 24SWG wire-loop into 0.2ml of 
sterile distilled water in a 7ml Bijou bottle containing 2‐3mm glass beads. It was 
votexed for 30 seconds to make an uniform suspension. 3.8ml of sterile distilled 
water was added to make the suspension comparable to Mc Farlands opacity tube 
No. 1. Suspension was allowed to stand on the bench so that coarse particles settle 
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down. From this suspension a ten-fold dilution was made by adding 0.2 ml to 1.8 
ml sterile distilled water (1/10). Two further serial dilutions were prepared in a 
similar manner. One standard loopful (3mm diameter, 27SWG) was inoculated onto 
drug free as well as drug containing LJ SLOPES. 
Standard Strain “M.tuberculosis H37RA” was tested with each new batch of 
medium. 
Incubation: 37degree centigrade for 28 – 42 days 
Table 1: Growth recording 
+++         Confluent Growth 
++   >100 Colonies 
1‐99 colonies Actual number of colonies 
 
When number of colonies on a given dilution is <15, the number of colonies with 
next larger inoculums were counted or estimated if >100. 
Interpretation of DST: 
Based on the 42 days readings, the number of organisms resistant to each drug 
concentration was expressed as a percentage of the number of organisms growing 
on a drug free slope. The slopes were selected for estimating the growth on drug 
free and drug containing media. The colonies on LJ with 5 to 100 colonies both on 
drug free and drug containing media were enumerated. 
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The proportion % is calculated with the following formula: 
Average no. of colonies of drug containing media/ Average no. of colonies on drug 
free media * 100  
<1% Susteptible, >1% Resistant. 
4.10.2 The index test – Pyrosequencing assay: 
The Pyrosequencing assay includes three essential steps – 
1) DNA Extraction. 
2) Amplification of the target gene segments by Polymerase chain reaction (PCR). 
3) Capture of the single-stranded DNA on streptavidin-sepharose beads followed by 
sequencing with Pyrosequencing technology. 
Step 1 – DNA extraction 
Requirements: 
 Culture isolates of MTB (Resistant/Susceptible) 
 Smear loop  
 Eppendorf tubes 
 50mM Tris-HCl (pH 8.0) 
 pH meter 
 Chloroform 
 Dry bath ( temperature to be set for 85 °C for 30 minutes) 
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 Nuclease free water 
 Pipettes 
 Pipette tips (200 μL, 1000 μL) 
 Vortex machine and centrifuge 
 Nanodrop (Quantification of DNA) 
 
Procedure:        
i) A loopful of bacterial colonies were taken from the LJ medium and emulsified in 
1 ml of 50 mM Tris-HCl (pH 8.0).  
ii) The bacterial cells were inactivated and lysed by placing it in a dry bath at 85°C 
for 30 minutes.  
iii) The suspension of lysed cells were then allowed to cool to room temperature 
and centrifuged at a relative centrifugal force of 12,000 × g for five minutes. 
Subsequently the supernatant was decanted and the pellet was retained.  
iv) The pellet was then suspended in 100μl of 1:1 mixture of chloroform and water 
and the suspension was vortexed for five minutes. This was followed by 
centrifugation at a relative centrifugal force of 12,000 × g for five minutes. 
v) The supernatant containing the extracted DNA was subsequently removed and 
subjected to quantification by measurement of optical density at 260 nm using 
Nanodrop.  
vi) The extracted DNA of the isolates were diluted to around 20 ng/μl-40 ng/μl and 
stored at −20°C for further molecular work up (92). 
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Step 2 – Amplication of target genes by polymerase chain reaction 
Requirements: 
 DNA Extract 
 Pyro PCR master mix (Qiagen) 
 Primer set (Forward and Reverse Primers) Lin et. al. (90). 
 Nuclease free water 
 Coral load (10X)  
 Microtubes 
 Pipettes 
 Pipette tips (10μL, 20μL, 200μL) 
 Vortex machine and centrifuge 
 Thermal cycler 
 Electrophoresis gel and tank 
 Gel documentation system 
Primers: 
The insertion sequence “IS6110” was used as the molecular target for identification 
of Mtb Complex. The molecular targets used for determination of drug resistance 
are as follows – 
1. For Rifampicin (RIF) – RIF resistance-determining region (RRDR) of rpoB, 
2. For Fluroquinolones (FQs) – Quinolone resistance-determining region 
(QRDR) of gyrA 
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3. For the injectable drugs – Capreomycin  (CAP) and Kanamycin (KAN) – rrs 
and eis promoter region  
Either the forward or the reverse primers were biotinylated. The PCR primers used 
are listed in table 2. 
Table 2: PCR Primer Sequence Lin et. al. (90) 
Drug Locus and primers Sequence 
MTB 
Complex  
IS6110 
Forward 
Reverse 
 
 
Biotin-CCGCCAACTACGGTGTTTA 
Reverse CAGGCCGAGTTTGGTCAT 
RIF rpoB 
Forward 
Reverse 
 
TTTCGATCACACCGCAGACGTT 
Biotin‐AAGGCACGCTCACGTGACAGAC 
FQ gyrA 
Forward 
Reverse 
 
AATGTTCGATTCCGGCTTCC 
Biotin‐CGGGCTTCGGTGTACCTCAT 
AMK 
CAP 
KAN 
rrs 
Forward 
Reverse 
eis 
Forward 
Reverse 
 
TAAAGCCGGTCTCAGTTCGGAAC 
Biotin‐CAGCTCCCTCCCGAGGGTTA 
 
Biotin-GGCTACACAGGGTCACAGTC 
GCCAGACACTGTCGTCGTAATATTC 
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Master mix preparation: 
All the reagents required for performing PSQ assay was obtained from Qiagen. The 
concentrations of the different components of the PCR mix for one reaction are 
given below in Table 3.  
Table 3: Master mix preparation 
Reagent  Volume per reaction 
PyroMark PCR Master Mix, 2X 18.75 μL  
 
CoralLoad Concentrate, 10X 3.75 μL 
Primer 3.75 μL 
Nuclease free water 6.25 μL 
DNA Extract 5 μL 
Total Reaction Volume 37.5 μL 
 
Procedure for amplification: 
1) The master mix was prepared for the appropriate number of reactions with the 
above template. Separate master mixes were prepared for the each reactions.  
2) Appropriate number of 0.5ml PCR tubes were labelled appropriately, and the 
master mix was distributed in them.  
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3) DNA extracts were removed from the storage area, brought to room temperature 
and spun briefly in a micro centrifuge.  
4) 5μL of the DNA extract was added to each tube appropriately.  
5) Amplification was carried out in Veriti TM Thermal Cycler (Applied Biosystem, 
California, USA). 
Cycling conditions: (Lin et. al.) (90). 
Table 4: Cycling conditions 
Steps Time Temperature 
Initial activation 15 min 95 °C 
Cycling:   
i) Denaturation 15 sec 94 °C 
ii) Annealing 30 sec 60 °C 
iii) Extension 20 sec 72°C 
No. of cycles 50  
Final extension 5 min 72°C 
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Post amplification analysis:  
1) 2% agarose gel containing 0.5 μg/ml ethidium bromide was freshly prepared. 
Five microliters of each amplicon was mixed well and used for agarose gel 
electrophoresis to detect the amplified product. 
2) The test amplicons were loaded in appropriate wells. 100bp molecular ladder 
was used. The amplified products were then subjected to electrophoresis. The 
electrophoresis was performed at 140 volts for 30 minutes.  
4) The gel was visualized by ultraviolet radiation using Quantity One® (version 
4.6.2) software in the gel documentation system (Bio-Rad, Hercules, California, 
USA).  
5) Isolate amplicons showing discrete desired bands (Fig.12, 13, 14) were taken up 
for Pyrosequencing assay. 
 
                    
Figure 12: Gel picture showing rpoB bands of the control isolate (H37RA) and test 
isolates. 
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1000bp 
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Figure 13: Gel picture showing rrs band and gyrA band of the control isolate (H37RA) 
and test isolates. 
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Figure 14: Gel picture showing eis promoter region of the control isolate (H37RA) 
and test isolates. 
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Step 3: Pyrosequencing assay 
The following equipment and reagents were required for sample preparation for 
Pyro Mark Q24 Instrument. All reagents were allowed to come to room temperature 
(15–25°C) before starting. 
Requirements: 
 PyroMark Q24 Vacuum Workstation 
 Plate mixer for immobilization of beads 
 Heating block – 80°C 
 PyroMark Q24 Plate 
 24-well PCR plate or strips 
 Strip caps 
 Streptavidin Sepharose High Performance (34μm, 5 ml, GE Healthcare) 
 Sequencing primer 
 High-purity water (Milli-Q 18.2 MΩ x cm or equivalent) 
 Ethanol (70%) 
 PyroMark Binding Buffer 
 PyroMark Denaturation Solution 
 PyroMark Wash Buffer concentrate 
 PyroMark Annealing Buffer 
 Pyro Mark Q24 Instrument (QIAGEN) 
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Immobilizing the PCR products to Streptavidin Sapharose High Performance 
beads: 
This procedure was done for immobilization of template DNA to Streptavidin 
Sapharose High Performance beads (GE Healthcare) prior to analysis on the 
PyroMark Q24 system. 
Procedure: 
1) The bottle containing the Streptavidin Sapharose High Performance beads was 
gently shaken until the solution became homogenous. 
2) Master mix for DNA immobilization was prepared according to table 5. A 
volume 10% greater than that required for total number of reactions to be 
performed was prepared. 
Table 5 : Master mix for DNA immobilization 
Component Volume in μl 
Streptavidin Sapharose High Performance 2 
PyroMark Binding buffer 40 
Water  13 
Total volume 55 
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3) 55μl of the master mix was added to wells of a 24-well PCR plate or strips. 
4) 20μl to 30μl biotinylated PCR (based on the brightness if band in gel picture) 
product was added to appropriate wells containing the master mix to give a total 
volume of 80μl. PCR plate or strips were sealed using strip caps. The PCR plate 
was agitated using an orbital shaker at 1400 rpm for 5–10 min at room temperature 
(15–25°C). 
   
Figure 15: Pyrosequencing Workflow (93). 
 
Preparation of samples prior to Pyrosequencing analysis on the PyroMark Q24: 
Procedure: 
1. A sufficient amount of each sequencing primer was diluted in PyroMark 
annealing buffer (22.5μl of annealing buffer and 3μl of sequencing primer (10X) 
were pipetted into each well). 
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The details of the sequencing primers are in the table 6. (Lin et.al.) (90). 
Table 6 : Sequencing primers for the target genes 
Drug  Locus Sequencing primers 
RIF rpoB 
Sequencing, for codons 507–521 
Sequencing, for codons 522–533 
 
GCGATCAAGGAGTTCTTC 
CAGAACAACCCGCTG 
FQ gyrA 
 
CAACTACCACCCGCA 
AMK, 
CAP, 
KAN 
rrs 
eis 
CTTGTACACACCGCC 
CAGACACTGTCGTCG 
 
2. After diluting the sequencing primers to 0.3μM with PyroMark Annealing 
Buffer, 25μl was dispensed into appropriate well of the PyroMark Q24 Plate. Then 
the plate was positioned on the workstation. 
3. The workstation troughs were filled according to the Figure 16. 
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Figure 16: PyroMark Q24 Vacuum station. Placement of PCR strips and PyroMark Q24 
plate on the vacuum work station. 
 
4. Vacuum was applied to the tool by turning ON the vacuum switch. 
5. The filter probes of the vacuum tool were carefully lowered into the PCR strips 
to capture the beads containing immobilized template. The probe was held in place 
for about 15 seconds. 
6. The vacuum tool was then transferred to the trough containing 40ml 70% ethanol 
(Fig. 16). The filter probe was then flushed for about 5 seconds. 
PyroMark Q24 plate with 
sequencing primers 
Strip tubes with PCR 
product immobilized on 
sepharose beads 
Vacuum tool 
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7. The vacuum tool was then transferred to the trough containing 40 ml 
denaturation solution (Fig.16). The filter probe was then flushed for about 5 
seconds. 
8. The vacuum tool was then transferred to the trough containing 50 ml wash buffer 
(Fig. 16). The filter probe was then flushed for about 10 seconds. 
9. The vacuum tool was raised up and back beyond 90˚ vertical, for about 5 seconds 
to drain liquid from the filter probes. 
10. The vacuum switch on the tool was closed while the vacuum tool was held over 
the PyroMark Q24 Plate. 
11. The beads were released in the PyromarkQ24 Plate by lowering the filter probes 
into the diluted sequencing primer and then moving the tool gently from side to 
side. 
12. The vacuum tool was then transferred to the trough containing high-purity water 
(Fig. 16) and agitated for about 10 seconds. 
13. The filter probes were washed by lowering the probes into high purity water 
(Fig. 16) and applying vacuum. The probes were then flushed with 70ml high purity 
water. 
14. The vacuum tool was raised to beyond 90˚ vertical for about 5 seconds to drain 
liquid from the filter probes. Then the vacuum was switched OFF and the tool was 
stored in the “Parking” position (Fig. 16). 
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Annealing sequencing primers to DNA strands: 
The PyroMark Q24 Plate with immobilized DNA was placed in a pre-warmed 
PyroMark Q24 Plate Holder. The Pyrosequencing samples were heated on a heating 
block at 80°C for 2 minutes. Then the plate was removed from the holder and the 
samples were allowed to cool to room temperature (15–25°C) for at least 5 minutes. 
The cooled plate was then processed in the PyroMark Q24 system. 
Setting up the run: 
1. In the shortcut browser, the folder in which the run file is to be placed was right-
clicked and “New Run” was selected from the context menu. The file name was 
typed and “Enter” was pressed. 
2. “Instrument Method” was selected as per the instructions supplied with the 
reagents and cartridge used. 
3. An assay was added to each well used, e.g., by dragging an assay from the 
shortcut browser to a well or a selection of wells. A well gets coloured according to 
the assay loaded into the well. 
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Figure 17: Setting up a run 
4. To enter a sample ID or note, the cell was selected and the text was entered. The 
selected cell gets highlighted with a blue background colour. 
6. Click in the toolbar. 
7. A list of required volumes of reagents and the plate setup was printed; “Pre Run 
Information” was selected from the “Tools” menu and then, when the report 
appeared, “ok” was clicked. 
8. The run file was closed and copied in to one of the pen drives supplied. The run 
file was then processed by inserting the pendrive into the USB port at the front of 
the PyroMark Q24 Instrument. 
Preparation of Pyro Mark Gold Q24 Reagents and Running the PyroMark Q24: 
Procedure: 
1. The freeze-dried enzyme and substrate mixtures were dissolved each in 620 μl of 
water and mixed by swirling the vial gently. 
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2. The reagents and the PyroMark Q24 Cartridge were allowed to reach the ambient 
temperature. 
3. The PyroMark Q24 cartridge was loaded with the appropriate volumes of 
nucleotides (dATP, dCTP, dGTP, dTTP) enzyme and substrate mixes according to 
figure 18, as given by the pre-run information.  
 
Figure 18: Illustration of PyroMark Q24 Cartridge as seen from above. 
 
4. After loading the cartridge the pyro sequencing plate was loaded on to the 
PyroMark24 machine. The assay file saved on to the pen drive was selected and the 
Run was started. 
Analysis of run: 
1. The processed run file was moved from the USB stick to a computer running 
PyroMark Q24 Software. 
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2. The run file was opened by double-clicking the run file in the shortcut browser. If 
several assay types were included, the analysis mode was selected in the dialog box 
that opened. 
 
Analysis modes: 
1. PyroMark Q24 Software has three analysis modes: AQ, CpG, and SQA. 
2. The “SQA” mode was selected in the toolbar. 
Result: 
Quality colors 
         Blue: Passed 
        Yellow: Check 
         Red: Failed 
        White: Not analyzed* 
 
* Either analysis is not supported by the software (e.g., analysis of SNP when in the 
CpG mode) or the variable position has been deselected by the user (AQ and CpG 
assays only). 
Representative Pyrogram results are shown in Figures 19-26. 
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Figure 19: rpoB Pyrogram H37RA (Wild type sequence). 
 
 
 
 
 
Figure 20: rpoB Mutant sequence TCG531TTG 
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Figure 21: gyrA Pyrogram H37RA (Wild type sequence) 
 
 
Figure 22: gyrA Mutant sequence (GAC94GGC) 
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Figure 23: rrs H37RA (Wild type sequence) 
 
 
 
       Figure 24: rrs Mutant sequence (A1401G) 
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   Figure 25: eis promoter H37RA (Wild type sequence) 
 
 
Figure 26: eis promoter mutant sequence (C12T) 
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5. Results  
5.1 Demographic data: 
During the study period of 1 year 10 months, from November 2014 to August 2016, 
64 MTB clinical isolates were taken for the study. The samples were received in the 
Microbiology laboratory as part of routine diagnostics for mycobacterial drug 
resistance testing (agar proportion method).   
Based on the inclusion and the exclusion criteria, 64 MTB isolates from clinical 
samples on which first line (STM, INH, RIF, EMB) and second line (OFLOX, 
CAP, KAN, ETH) mycobacterial drug susceptibility testing were done, were  
included in the study. 
 
Figure 27: The geographical distribution of MTB clinical isolates included in the study 
from India. 
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Thus the following the number of isolates were used for evaluation by PSQ assay: 
1. Rifamipicin = 57 
2. Fluoroquinolone 
a. Ofloxacin =50 
3. Injectable agents 
a. Capremycin = 51 
b. Kanamycin =  51 
The MTB clinical isolates were found to be resistant or susceptible based on the 
agar proportion method. The susceptibility profile of the MTB clinical isolates 
included in the study is depicted in Figure 28. 
 
Figure 28: Susceptibility pattern of MTB clinical isolates included in the study. 
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5.2 Mutations detected by PSQ and their comparison with phenotypic DST: 
5.2.1 RIF Resistance: 
Drug susceptibility results were available for 57 isolates, for which PSQ was 
performed. Among the 57 isolates, 40 were phenotypically resistant to RIF. PSQ 
assay detected a total of 6 unique mutations and combinations of mutation across 
the RRDR region in the RIF resistant isolates. The most predominant mutation 
observed in rpoB gene was the “TCG531TTG” mutation, which was detected in 33 
(82%) of the 40 RIF-resistant isolates. 
Three isolates were phenotypically RIF-sensitive, but were found to have mutation 
in the rpoB gene when PSQ was performed. The mutations observed in these 
isolates were at codon 511 (Leu511Pro). The performance of the PSQ assay for the 
detection of RIF resistance in comparison to phenotypic DST is summarized in 
Table 7.  
 
 
 
 
 
 
 
77 
 
Table 7: Mutations in rpoB gene and their association with phenotypic DST results 
Locus Mutation  Amino acid  
change 
No of 
isolates 
       DST Results 
Resistant Susceptible 
rpoB TCG531TTG S531L 33 33 0 
GAC516GTC D516V 3 3 0 
GAC516TAC + 
CTG511CGG 
D516Y+L511R 1 1 0 
GAC516TAC D516Y 1 1 0 
CAC526CTC H526L 1 1 0 
TCG531TGG S531W 1 1 0 
CTG511CCG L511P 3 0 3 
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The diagram below shows the frequency of occurrence of mutations in rpoB gene 
among the RIF resistant isolates included in the study, which were detected by the 
pyrosequencing assay. 
 
Figure 29: Frequency of occurrence of mutations in rpoB gene among the RIF resistant 
isolates 
 
Table 8: Diagnostic accuracy of PSQ as compared to conventional DST for the detection 
of Rifampicin resistance in MTB clinical isolates. 
 DST (PROPORTION METHOD) TOTAL 
RESISTANT SUSCEPTIBLE 
PSQ – RIF 
RESISTANT 
40 0 40 
PSQ – RIF 
SUSCEPTIBLE 
0 17 17 
TOTAL 40 17 57 
82%
7%
2%
3%
3% 3%
Frequency of rpob gene mutations in percentage
TCG531TTG
GAC516GTC
GAC516TAC+CTG511CCG
GAC516TAC
TCG531TGG
CAC526CTC
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The sensitivity and specificity was 100% (87% - 100%) and 100 % (73% - 100%) 
respectively. The positive predictive value and the negative predictive value was 
found to be 100%. The agreement between the PSQ results and conventional DST 
results for RIF was 100% (kappa=1, p value <0.001). 
5.3 PSQ in comparison with Xpert MTB/Rif assay: 
Xpert MTB/Rif assay results was available for 56 MTB clinical isolates. The 
agreement between Xpert MTB/Rif assay and PSQ assay was found to be 98.2% 
(Kappa=0.953, p value < 0.001). 
Table 9: Diagnostic accuracy of PSQ in comparison with Xpert MTB/Rif assay 
 Xpert MTB/ Rif assay TOTAL 
RESISTANT SUSCEPTIBLE 
PSQ – RIF 
RESISTANT 
41 1 39 
PSQ – RIF 
SUSCEPTIBLE 
0 14 17 
TOTAL 41 15 56 
 
The sensitivity and specificity was 100% (91.4%-100%) and 93.33% respectively. 
The positive predictive value and the negative predictive value was 97.62 % (87.43-
99.94%) and 100% (76.84% - 100%) respectively. One isolate was susceptible by 
Xpert MTB/Rif assay and resistant by the PSQ. This isolate had a mutation in 
codon 531 (TCG531TTG), however this isolate was resistant by the gold standard 
conventional DST testing.  
80 
 
5.2.2 Fluoroquinolone Resistance: 
DST results were available for the 50 isolates among which 28 were resistant to 
fluoroquinolone (FQ). PSQ detected a total of 6 unique mutations, across the gyrA 
gene (QRDR). Twenty resistant isolates showed mutations in the 94th codon of 
gyrA: 15 GAC- GGC, 2 GAC- GCC, 1 GAC- TAC, 1 GAC- CAC, 1 GAC-AAC. 
All the resistant isolates with these single nucleotide polymorphisms (SNPs) were 
phenotypically resistant to Ofloxacin (agar proportion method). Eight isolates 
showed a 90 GCG- GTG mutation. The performance of the PSQ assay for the 
detection of FQ resistance in comparison to phenotypic DST is summarized in 
Table 10.  
Table 10: Mutations in gyrA gene and their association with phenotypic DST results 
Locus Mutation  Amino acid  
change 
No of 
isolates 
       DST Results 
Resistant Susceptible 
gyrA GAC94GGC D94G 15 15 0 
GAC94GCC D94A 2 2 0 
GAC94CAC D94H 1 1 0 
GAC94AAC D94N 1 1 0 
GAC94TAC D94Y 1 1 0 
GCG90GTG A90V 8 8 0 
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The diagram below shows the frequency of occurrence of mutations in gyrA gene 
among the FQ resistant isolates included in the study, which were detected by the 
pyrosequencing assay. 
 
Figure 30: Frequency of mutations detected in gyrA gene among the FQ resistant isolates 
by PSQ assay 
 
Table 11: Diagnostic accuracy of PSQ as compared to conventional DST for the detection 
of FQ resistance in MTB clinical isolates. 
 DST (PROPORTION METHOD) TOTAL 
RESISTANT SUSCEPTIBLE 
PSQ – FQ 
RESISTANT 
28 0 28 
PSQ – FQ 
SUSCEPTIBLE 
0 22 22 
TOTAL 28 22 50 
55%
7%
3%
3%
3%
29%
Frequency of gyrA gene mutations in percentage
GAC94GGC
GAC94GCC
GAC94CAC
GAC94AAC
GAC94TAC
GCG90GTG
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The sensitivity was 100% (82.8% - 100%) and specificity was 100% (78.9% - 
100%). The positive predictive value and negative predictive value was 100% and 
100% respectively. The agreement between the two test was 100% (kappa = 1.00 
and p value <0.001). 
5.2.3 Second Line Injectable (SLI) Drug Resistance: 
For the second line drugs Capreomycin (CAP) and Kanamycin (KAN), DST results 
were available for 51 isolates among which 15 were phenotypically resistant to 
CAP and 14 were phenotypically resistant to KAN. Among these 10 isolates were 
resistant to both the SLI (CAP, KAN). In these 10 isolates PSQ detected a 1401 A- 
G mutation in 5 isolates and 1402 C- T mutation in 1 isolate in the rrs gene region. 
The remaining 5 isolates did not show any mutation in the rrs gene segments 
evaluated suggesting that mutation might exist in other sites of rrs gene. Thus eis 
promoter gene region was also evaluated by the PSQ assay for the isolates resistant 
to SLI, since eis promoter mutations confer lower levels of CAP resistance and low 
to moderate levels of KAN resistance The eis promoter mutation C-12T was found 
in one of the isolates which was susceptible to CAP and resistant to KAN.  
The performance of the PSQ assay for the detection of SLI resistance in comparison 
to phenotypic DST is summarized in Table 12. 
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Table 12: Mutations in rrs and eis promoter regions and their association with phenotypic 
DST results 
Locus Mutation  No of isolates   DST Results (CAP) DST Results (KAN) 
Resistant Susceptible Resistant Susceptible 
rrs A1401G 5 5 0 5 0 
C1402T 1 1 0 1 0 
eis C12T 1 0 0 1 0 
 
The diagram below shows the frequency of occurrence of mutations in rrs and eis 
promoter region among the SLI resistant isolates included in the study.
 
Figure 31: Frequency of mutations detected in rrs and eis promoter regions among the SLI 
resistant isolates by PSQ assay  
rrs A1401G
72%
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Table 13: Diagnostic accuracy of PSQ as compared to conventional DST for the detection 
of CAP resistance in MTB clinical isolates. 
 DST (PROPORTION METHOD) TOTAL 
RESISTANT SUSCEPTIBLE 
PSQ – CAP 
RESISTANT 
6 0 6 
PSQ – CAP 
SUSCEPTIBLE 
9 36 45 
TOTAL 15 36 51 
 
The sensitivity was 40% (16.3% - 67.7%) and specificity was 100% (85.8% - 
100%). The positive predictive value and negative predictive value was 100% 
(42.1% - 100%) and 80% (65.4% - 90.4%) respectively. The agreement between the 
two test were 82.35% (kappa = 0.48 and p value <0.001). 
Table 14: Diagnostic accuracy of PSQ as compared to conventional DST for the detection 
of KAN resistance in MTB clinical isolates. 
 DST (PROPORTION METHOD) TOTAL 
RESISTANT SUSCEPTIBLE 
PSQ – KAN 
RESISTANT 
7 0 7 
PSQ – KAN 
SUSCEPTIBLE 
7 37 44 
TOTAL 14 37 51 
 
With the addition of eis promoter region in the PSQ assay, the sensitivity for 
detecting SLI (KAN) resistance increased to 50% (23.04% - 76.96%) and 
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specificity was 100% (90.51% - 100%). The positive predictive value and negative 
predictive value was 100% (59.04% - 100%) and 84.09% (69.93% - 93.36%) 
respectively. The agreement between the two test were 86.27% (kappa = 0.59 and p 
value <0.001). 
5.4 Comparison of PSQ assay and Line Probe assay in detecting drug resistant 
mutations: 
A prospective study was conducted in our setting, Christian Medical College, a 
tertiary care centre in South India, where the performance of line probe assay 
(GenoTypeMTBDRplus) was compared with culture and the Xpert MTB/Rif assay 
on sputum specimens of suspected MDR pulmonary tuberculosis patients (January 
2013 to June 2013). In this study, among the patients who were resistant to 
Rifampicin, we observed predominantly absence of a wild-type 8 band (covering 
codons 530-533) without a corresponding mutation band in 16 of the sputum 
samples, along with occurrence of MT3 band (S531L) in 10 of the sputum samples 
(n=35). In comparison to our study, PSQ also showed predominantly TCG531TTG 
(S531L) mutation in 82% of the Mtb clinical isolates 
Another prospective study (unpublished data) being done in our setting also 
evaluating the performance of GenoType MTBDRsl in detecting resistance of Mtb 
clinical isolates to 2nd line anti-TB drugs. In this study among the FQ resistant 
isolates we observed predominantly MUT3 band (D94G) with the absence of the 
corresponding wild-type 3 band (covering codons 92-97) in 12 (41.37%) of the 
clinical MTB isolates (n=29) and among the aminoglycoside resistant isolates we 
predominantly observed MUT1 band (A1401G, C1402T) with the absence of 
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corresponding wild-type 1 band (covering codons 1401, 1402) in 3 of the clinical 
MTB clinical isolates (n=4). 
The results were similar to our study, where the most common mutation was 
GAC94GGC (D94G) in 15(55%) of the FQ resistant clinical isolates (n=28) and 
among the aminoglycosides A1401G being the most common mutation in 5 of the 
clinical isolates (n=10 i.e. resistant to both CAP & KAN). 
5.5 Turnaround time of tests: 
 
Test Turnaround time 
1st line & 2nd line DST 6 weeks 
Xpert MTB/Rif assay 2 hours 
Line probe assay 6-8 hours 
Pyrosequencing 6 hours 
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6. Discussion  
Bacteriological methods are labour-intensive and time-consuming for the detection 
of resistance to most of the anti-TB drugs, but they are highly sensitive and specific 
and considered the gold standard DST methods. WHO approved methods such as 
Xpert MTB/Rif assay and Line Probe assays are rapid but have fixed targets for 
detection and cannot detect silent mutations or mutations outside the target region. 
Sequencing techniques overcome these limitations. Therefore we evaluated 
Pyrosequencing, one of the sequencing techniques for detection of mutations 
associated with resistance to Rifampicin and Second-line anti-TB drugs in clinical 
isolates of M. tuberculosis.  
Pyrosequencing is a rapid, robust and high-throughput diagnostic sequencing 
technique that is easy to perform. In this method, multiple strains can be 
simultaneously sequenced in a 24-well plate. The assay is capable of 
simultaneously detecting Mtb and the most common mutations conferring 
phenotypic resistance to Rifampicin, Fluoroquinolones and Second line injectable 
agents. It can also be used to detect novel mutations within the targeted gene 
regions. PSQ also provides a detailed sequence information, thereby the sequence 
can be interpreted based on the current and evolving knowledge on phenotypic 
expression of the drug-resistant Mtb strains. The gold standard for the detection of 
drug resistance in tuberculosis is the bacteriological methods. Thus, we compared 
the results of Pyrosequencing with the 1% agar-proportion method of drug 
susceptibility testing in MTB clinical isolates. 
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6.1 PSQ for the detection of Rifampicin resistance: 
Rifampicin is a tuberculocidal drug used for treating TB. RIF resistance is used as a 
surrogate marker for MDR-TB. The accuracy of molecular diagnostics for the 
detection of RIF resistance is critical, since it can influence in taking early clinical 
decisions. The frequency of mutations detected in rpoB gene in RIF-resistant 
isolates by the PSQ assay are consistent with the other reports published in the 
literature, thus demonstrating the importance of the RRDR hotspot region in the 
resistance of MTB clinical isolates (94) (95) (96) (97). Several studies have 
indicated that RRDR region contributes to around 90–95% of RIF-resistance 
(97,98). Notably, majority of MTB clinical isolates (82%) had mutations in codon 
531, which is similar to the previously published reports (92) (99) (100). The other 
mutations were observed in codons 516, 526, and 511. 
The PSQ assay detected mutation in all the Rifampicin resistant isolates (n=40) 
included in the study. Additionally it also detected mutation in 3 isolates that were 
determined to be phenotypically susceptible. The mutation observed in these 3 
isolates were at codon 511 (CTG511CCG). This mutation can occur in other RIF 
resistant strains along with other mutation, but the occurrence of  CTG511CCG 
mutation alone confers low predictive value for rifampicin resistance (101). This 
mutation is known to be documented as “disputed mutations” conferring “low-
level” Rifampicin resistance (Van duen et. al.) (102). Since these mutations are 
already known to have inconsistent RIF-DST results, they were excluded for 
specificity analysis of our study (92) (102) (103). 
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The sensitivity and specificity of the PSQ assay for detecting RIF resistance was 
100% (91.19% - 100%) and 100% (69.15 – 100%) respectively, which was in 
concordance with previously published studies (90) (89) (101) (104).   
The sensitivity and specificity of the PSQ assay in comparison with the Xpert 
MTB/Rif assay was 100% and 93.33% respectively. PSQ detected mutation in one 
of the isolates at codon 531 (TCG531TTG), which was susceptible by Xpert 
MTB/Rif assay. However it was resistant by the gold standard conventional DST 
testing. This may be a false-negative result of Xpert MTB/RIF assay due to mixed 
M.tuberculosis complex infections. Studies have shown that the Xpert assay failed 
to detect RIF resistance in vitro when <90% of the organisms in the sample were 
RIF resistant (105). 
6.2 PSQ for the detecting of fluoroquinolone resistance 
The main cellular target for fluoroquinolone in Mtb is “the DNA gyrase enzyme” 
(type II topoisomerase). It has two A and two B subunits which are encoded by 
gyrA and gyrB genes, respectively. The genetic mechanism of resistance to FQs is 
due to QRDR region mutations of gyrA and gyrB resulting in changes in the DNA 
gyrase enzyme. Studies have shown that around  approximately 60% to 90% of Mtb 
clinical isolates with FQ resistance have mutations in the QRDR of gyrA, 
commonly in “codons 88, 90, 91, and 94” (106,107) which is similar to our study, 
roughly 55% of the mutations occurred in the 94th  codon region. The gyrB locus 
was not included in our study, as mutations in this gene occur at a much less 
frequency with lower sensitivity and specificity. They commonly co-occur with 
gyrA mutations. Among the susceptible and resistant clinical isolates there was 
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uniform distributions of “gyrA S95T mutation” (92%), which is similar to the 
previous studies published. This mutation is regarded as polymorphism which does 
not confer FQ resistance (104,108). 
The sensitivity and specificity of the PSQ assay for FQ was 100% and 100% 
respectively. This may be due to the smaller sample size. However there are studies 
in regard with reduced sensitivity of the PSQ assay in detecting FQ resistance. This 
is due to the varied frequency of occurrence of mutations of the M.tuberculosis in a 
particular geographic region or may be due other resistance mechanisms like efflux 
pumps (101,104,109).  
6.3 PSQ for the detection of Second line injectables: 
With regard to the SLI, the mutations most commonly associated with resistance 
are the “A1401G mutation”, followed by “C1402T and G1484T mutations” in the 
rrs gene. Our assay can only detect the “A1401G and C1402T mutations”, and 
another primer set is needed to detect the “G1484T mutation”. Due to the low 
prevalence of the above mutation we did not include it in our study. With less 
number of resistant strains tested, our assay showed 100% specificity for detecting 
CAP and KAN resistance. But, the sensitivity was low for detecting CAP resistance 
(40%). For KAN, there was an increase in the sensitivity to 50% due to the addition 
of eis promoter gene in the PSQ assay. Other PSQ studies have also shown similar 
increase in sensitivity with the inclusion of eis promoter gene in the PSQ assay 
(109,110)  
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The review article published by Georghiou et.al. has shown that the rrs 1401 
mutation did not detect greater than 80% of Mtb strains globally that were resistant 
to CAP and AMK. It also did not detect 60% of KAN resistant Mtb strains. For 
improving the sensitivity and specificity in the detection of SLI, other SNPs in 
the “tlyA and gidB genes” can be considered as promising markers in improving the 
clinical and diagnostic utility of future molecular methodologies to the second line 
injectable drugs (111).  
6.4 PSQ versus LPA: 
The WHO had approved Line probe assay (LPA) for the detection of mutations 
conferring resistance to INH and RIF, commercially available as GenoType 
MTBDRplus (Hain Lifescience, Nehren, Germany). LPAs targeting resistance to 
second-line anti-TB drugs, GenoType MTBDRsl (Hain Lifescience, Nehren, 
Germany) detect mutations in the gyrA gene, rrs gene and embB gene and they 
complement the Hain GenoType MTBDRplus LPA for the detection of XDR-TB. 
The sensitivity of these tests depends on the inclusion of various mutations 
conferring resistance to Mtb and the frequency at which these mutations are found 
in MTB strains in different geographical settings (112).  
A study conducted in our setting, evaluated the performance of GenoType 
MTBDRplus (113) and GenoType MTBDRsl (unpublished data) showed a similar 
result in regard to frequency of occurrence of mutation in Rifampicin and Second 
line drugs. Among the samples (n=35) evaluated by MTBDRplus, 46% had absence 
of a wild-type 8 band without a corresponding mutation band and 29% had 
presence of MUT3 band.  
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With regard to GenoType MTBDRsl evaluated on Mtb clinical isolates, the 
fluoroquinolone resistant isolates (n=29) predominantly had a MUT3 band (D94G) 
with the absence of the corresponding wild-type 3 band (41.37%) and the 
aminoglycoside resistant isolates predominantly had MUT1 band (A1401G, 
C1402T) with the absence of corresponding wild-type 1 band in 3 out of 4 the 
clinical Mtb isolates (n=4). 
The most common mutation picked up by LPA for rifampicin resistance covered 
the codon regions 530 to 533. GAC94GGC (D94G) for fluoroquinolone resistance 
and A1401G for second line injectable resistance. This was similar to the mutations 
picked up PSQ assay in our study. 
Though LPA detected the most common mutations, PSQ has an added advantage 
that it can pick up additional mutations. In a study published by Nikam et.al shows 
that, in the case of discrepant results, PSQ can be used as a valuable tool for rapidly 
evaluating LPA-indeterminate results instead of repeating phenotypic DST, as the 
PSQ technology appears to resolve discrepancies in line with phenotypic DST 
results (114) . 
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7. Limitations of the study 
a) Sample size: 
The sample size was limited in our study due to a lack of funds. A larger sample 
size would have helped us to evaluate PSQ better.  
b) Sensitivity of PSQ assay in detection of SLI: 
The lower sensitivity rates of PSQ for detection of second line injectables (CAP, 
KAN) reflect that the incomplete understanding of resistance mechanisms 
associated with SLI investigated in the study. Therefore sequencing of other genes 
encoding for other resistance mechanisms in SLIs would improve sensitivity of the 
PSQ assay. 
c) PSQ on Mtb clinical isolates: 
The real usefulness of Pyrosequencing would have been effective if it was 
performed on clinical samples, but due to the lack of fund and time, the PSQ assay 
could not be standardised on clinical samples.  
d)Technical aspects: 
Sequencing failures was also a limitation, due to which certain isolates were 
excluded from the study, even though they had DST results.  Georghiou et.al. in his 
study had stated that sequencing failures may be associated with the sequencing 
length of the given gene target (longer sequencing targets had more sequencing 
failures) (115).    
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8. Summary & Conclusion  
In summary, Of the 57 isolates tested for RIF resistance, 40 were phenotypically 
resistant to Rifampicin. By PSQ the most predominant mutation observed in rpoB 
gene was TCG531TTG (82%). Twenty eight of the 50 isolates were phenotypically 
resistant to FQ. Of these, 20 isolates showed mutations in the 94th codon of gyrA 
gene. The predominant mutation observed was GAC94GGC (55%). Of the 51 
isolates tested for resistance to aminoglycosides 10 were phenotypically resistant to 
CAP and KAN. Five of the 10 isolates had A1401G mutation. However, 4 of the 
resistant isolates had no mutation in the rrs gene segments evaluated suggesting 
that mutations exist in other sites of rrs gene. 
To conclude the data published by other molecular studies is comparable to our data 
(89,90,101,104,106,116)  demonstrating that PSQ assay can be used as a rapid and 
effective method for identification of Mycobacterium tuberculosis and also to detect 
mutations associated with drug resistance in Mtb clinical strains. The whole 
technique can be accomplished within 6 hours (from DNA extraction to reporting 
results) and integrated easily into the diagnostic laboratory work flow. It’s quite 
flexible, as the assay number and the choice of the target included can be adjusted 
easily. It can be used for investigation of a larger number of specimens. Another 
benefit of sequencing assays compared to probe based assays is the “discriminatory 
power at the genotypic level”. Sequencing can differentiate between silent and 
missense mutations can differentiate mutations not associated with resistance (104).  
The accuracy of  PSQ is comparable to that of other sequencing methods like 
Sanger sequencing (90,98) and the sequence information provided by PSQ assay 
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enables the users to know the association with  MICs (minimum inhibitory 
concentration) of the drugs with respect to each mutation, thus guiding treatment 
decisions. 
Pyrosequencing, however, cannot be an alternative to conventional DST. 
Phenotypic resistant strains lacking mutation in known “resistance-associated loci”, 
where there are multiple genetic bases for resistance or where all the mechanisms of 
resistance have not been identified, presents a problem for all molecular technique 
designed to detect mutations associated with resistance. However, issues like costs 
and complexities of testing additional sites limit the assays numbers that can be 
performed for each sample in clinical practice. This emphasizes the need for 
research that aims at identifying novel resistance mechanisms in M. tuberculosis.  
The rapidity along with a “multilocus sequencing” in parallel of several isolates 
makes Pyrosequencing an effective technique for screening of drug resistance in 
Mtb. As this technology is based on PCR, it has a greater utility to be further 
modified for application directly on clinical specimens. 
 
 
 
 
 
 
96 
 
9. Bibliography 
 
1.  Daniel TM. The history of tuberculosis. Respir Med. 2006 Nov;100(11):1862–
70.  
2.  History of Tuberculosis (TB) [Internet]. National Jewish Health. [cited 2016 
May 25]. Available from: 
https://nationaljewish.org/healthinfo/conditions/tb/history 
3.  CDC | TB | Drug-Resistant TB [Internet]. [cited 2016 May 25]. Available 
from: http://www.cdc.gov/tb/topic/drtb/ 
4.  Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. 
Surveillance of anti-tuberculosis drug resistance in the world: an updated 
analysis, 2007–2010. Bull World Health Organ. 2012 Feb 1;90(2):111–119D.  
5.  WHO | TB diagnostics and laboratory strengthening - WHO policy [Internet]. 
WHO. [cited 2016 May 15]. Available from: http://www.who.int/tb/areas-of-
work/laboratory/policy_diagnosis_pulmonary_tb/en/ 
6.  WHO | WHO guidelines on tuberculosis [Internet]. WHO. [cited 2016 May 
25]. Available from: 
http://www.who.int/publications/guidelines/tuberculosis/en/ 
7.  Tuberculosis (TB) and other mycobacterial diseases: diagnosis, screening, 
management and data - GOV.UK [Internet]. [cited 2016 May 25]. Available 
from: https://www.gov.uk/government/collections/tuberculosis-and-other-
mycobacterial-diseases-diagnosis-screening-management-and-data 
8.  SEARO | Revised National Tuberculosis Control Programme (RNTCP) – 
Guidelines for TB Control in India [Internet]. SEARO. [cited 2016 May 25]. 
Available from: 
http://www.searo.who.int/india/tuberculosis/topic/tb_rntcpguidelines/en/ 
9.  Organization WH. Global tuberculosis report 2015 [Internet]. World Health 
Organization; 2015 [cited 2016 May 8]. Available from: 
http://www.who.int/iris/handle/10665/191102 
10.  Millard J, Ugarte-Gil C, Moore DAJ. Multidrug resistant tuberculosis. BMJ. 
2015 Feb 26;350:h882.  
11.  WHO | What is multidrug-resistant tuberculosis (MDR-TB) and how do we 
control it? [Internet]. WHO. [cited 2016 May 9]. Available from: 
http://www.who.int/features/qa/79/en/ 
12.  Notice to Readers: Revised Definition of Extensively Drug-Resistant 
Tuberculosis [Internet]. [cited 2016 May 9]. Available from: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5543a4.htm 
97 
 
13.  Organization WH, others. Extensively drug-resistant tuberculosis (XDR-TB): 
recommendations for prevention and control. Wkly Epidemiol Rec. 
2006;81(45):430–432.  
14.  Organization and others - 2014 - Drug-resistant TB surveillance and response 
supp.pdf [Internet]. [cited 2016 May 9]. Available from: 
http://www.who.int/tb/publications/global_report/gtbr14_supplement_web_v3.
pdf 
15.  Annual Reports :: Central TB Division [Internet]. [cited 2016 May 9]. 
Available from: 
http://tbcindia.nic.in/index1.php?sublinkid=4160&level=1&lid=2807&lang=1 
16.  annual-tb-report-2015.pdf [Internet]. [cited 2016 May 9]. Available from: 
http://www.searo.who.int/tb/annual-tb-report-2015.pdf 
17.  Michael JS, John TJ. Extensively drug-resistant tuberculosis in India: A 
review. Indian J Med Res. 2012 Oct;136(4):599–604.  
18.  Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison’s 
Principles of Internal Medicine, 18th Edition. McGraw Hill Professional; 2011. 
4322 p.  
19.  admin. Manson’s Tropical Diseases 23rd Edition | PDF | 2014 | Medical 
Ebooks Free [Internet]. [cited 2016 May 9]. Available from: 
http://www.medbookzz.com/2015/01/manson-tropical-diseases-23rd-
edition.html 
20.  Ernst JD, Trevejo-Nuñez G, Banaiee N. Genomics and the evolution, 
pathogenesis, and diagnosis of tuberculosis. J Clin Invest. 2007 Jul 
2;117(7):1738–45.  
21.  Fu LM, Fu-Liu CS. Is Mycobacterium tuberculosis a closer relative to Gram-
positive or Gram-negative bacterial pathogens? Tuberc Edinb Scotl. 
2002;82(2–3):85–90.  
22.  Tille P. Bailey & Scott’s Diagnostic Microbiology. Elsevier Science Health 
Science; 2013. 1038 p.  
23.  Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A 
replication clock for Mycobacterium tuberculosis. Nat Med. 2009 
Feb;15(2):211–4.  
24.  Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles 
and Practice of Infectious Diseases. Elsevier Health Sciences; 2014. 5095 p.  
25.  Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, et al. The 
Peptidoglycan of Stationary-Phase Mycobacterium tuberculosis Predominantly 
98 
 
Contains Cross-Links Generated by l,d-Transpeptidation. J Bacteriol. 2008 
Jun;190(12):4360–6.  
26.  Kaur D, Guerin ME, Škovierová H, Brennan PJ, Jackson M. Biogenesis of the 
cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv Appl 
Microbiol. 2009;69:23–78.  
27.  Bansal-Mutalik R, Nikaido H. Mycobacterial outer membrane is a lipid bilayer 
and the inner membrane is unusually rich in diacyl phosphatidylinositol 
dimannosides. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4958–63.  
28.  Hett EC, Rubin EJ. Bacterial Growth and Cell Division: a Mycobacterial 
Perspective. Microbiol Mol Biol Rev MMBR. 2008 Mar;72(1):126–56.  
29.  Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, et al. MEROPENEM 
INHIBITS D,D-CARBOXYPEPTIDASE ACTIVITY IN 
MYCOBACTERIUM TUBERCULOSIS. Mol Microbiol. 2012 
Oct;86(2):367–81.  
30.  Girardin SE, Travassos LH, Hervé M, Blanot D, Boneca IG, Philpott DJ, et al. 
Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. 
J Biol Chem. 2003 Oct 24;278(43):41702–8.  
31.  Kieser KJ, Rubin EJ. How sisters grow apart: mycobacterial growth and 
division. Nat Rev Microbiol. 2014;12(8):550–62.  
32.  Tuberculosis (TB) Transmission and Symptoms [Internet]. [cited 2016 May 
12]. Available from: 
https://www.niaid.nih.gov/topics/tuberculosis/understanding/pages/transmissio
n.aspx 
33.  CDC | TB | Basic TB Facts [Internet]. [cited 2016 May 12]. Available from: 
http://www.cdc.gov/tb/topic/basics/default.htm 
34.  Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in 
Health-Care Settings, 2005 [Internet]. [cited 2016 May 12]. Available from: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1
_e 
35.  Tuberculosis: From an incurable scourge to a curable disease - journey over a 
millennium Sharma SK, Mohan A - Indian J Med Res [Internet]. [cited 2016 
May 12]. Available from: http://www.ijmr.org.in/article.asp?issn=0971-
5916;year=2013;volume=137;issue=3;spage=455;epage=493;aulast=Sharma 
36.  Narasimhan P, Wood J, MacIntyre CR, Mathai D. Risk Factors for 
Tuberculosis. Pulm Med. 2013 Feb 12;2013:e828939.  
37.  Zumla A, Raviglione M, Hafner R, Fordham von Reyn C. Tuberculosis. N 
Engl J Med. 2013 Feb 21;368(8):745–55.  
99 
 
38.  Crevel R van, Ottenhoff THM, Meer JWM van der. Innate Immunity to 
Mycobacterium tuberculosis. Clin Microbiol Rev. 2002 Apr 1;15(2):294–309.  
39.  Hunter RL. PATHOLOGY of POST PRIMARY TUBERCULOSIS of the 
LUNG: AN ILLUSTRATED CRITICAL REVIEW. Tuberc Edinb Scotl. 2011 
Nov;91(6):497–509.  
40.  Knechel NA. Tuberculosis: Pathophysiology, Clinical Features, and Diagnosis. 
Crit Care Nurse. 2009 Apr 1;29(2):34–43.  
41.  Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new 
insights into an old disease. Lancet Infect Dis. 2005 Jul;5(7):415–30.  
42.  Desikan P. Sputum smear microscopy in tuberculosis: Is it still relevant? 
Indian J Med Res. 2013 Mar;137(3):442–4.  
43.  Rieder HL, Kam KM, Kim SJ, Chonde TM, others. Priorities for tuberculosis 
bacteriology services in low-income countries: International Union Against 
Tuberculosis and Lung Disease. Paris Fr. 2007;  
44.  WHO | International Standards for Tuberculosis Care (ISTC) [Internet]. WHO. 
[cited 2016 May 15]. Available from: 
http://www.who.int/tb/publications/2006/istc/en/ 
45.  Organization WH. Automated real-time nucleic acid amplification technology 
for rapid and simultaneous detection of tuberculosis and rifampicin resistance: 
Xpert MT [Internet]. World Health Organization; 2013 [cited 2016 May 15]. 
Available from: http://www.who.int/iris/handle/10665/112472 
46.  Harries A. 11. What is the additional yield from repeated sputum examinations 
by smear microscopy and culture? TOMAN’S Tuberc. 2004;46.  
47.  WHO | Same-day diagnosis of tuberculosis by microscopy [Internet]. WHO. 
[cited 2016 May 15]. Available from: 
http://www.who.int/tb/publications/2011/tb_microscopy_9789241501606/en/ 
48.  Singhal R, Myneedu VP. Microscopy as a diagnostic tool in pulmonary 
tuberculosis. Int J Mycobacteriology. 2015 Mar;4(1):1–6.  
49.  Tuberculosis Division International Union Against Tuberculosis and Lung 
Disease. Tuberculosis bacteriology--priorities and indications in high 
prevalence countries: position of the technical staff of the Tuberculosis 
Division of the International Union Against Tuberculosis and Lung Disease. 
Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2005 Apr;9(4):355–
61.  
50.  Karstaedt AS, Jones N, Khoosal M, Crewe-Brown HH. The bacteriology of 
pulmonary tuberculosis in a population with high human immunodeficiency 
virus seroprevalence. Int J Tuberc Lung Dis. 1998 Apr 1;2(4):312–6.  
100 
 
51.  Khan EA, Starke JR. Diagnosis of tuberculosis in children: increased need for 
better methods. Emerg Infect Dis. 1995 Dec;1(4):115–23.  
52.  Manual for Sputum Smear Fluorescence Microscopy , RNTCP 2007: 
http://tbcindia.nic.in/pdfs/Flourescence Microscopy%20Manual.pdf - Google 
Scholar [Internet]. [cited 2016 May 16]. Available from: 
https://scholar.google.co.in/scholar?hl=en&q=Manual+for+Sputum+Smear+Fl
uorescence+Microscopy+%2C+RNTCP+2007%3A+http%3A%2F%2Ftbcindi
a.nic.in%2Fpdfs%2FFlourescence+Microscopy%2520Manual.pdf&btnG= 
53.  Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. 
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a 
systematic review. Lancet Infect Dis. 2006 Sep;6(9):570–81.  
54.  Cuevas LE, Al-Sonboli N, Lawson L, Yassin MA, Arbide I, Al-Aghbari N, et 
al. LED Fluorescence Microscopy for the Diagnosis of Pulmonary 
Tuberculosis: A Multi-Country Cross-Sectional Evaluation. PLOS Med. 2011 
Jul 12;8(7):e1001057.  
55.  Reza LW, Satyanarayna S, Enarson DA, Kumar AMV, Sagili K, Kumar S, et 
al. LED-Fluorescence Microscopy for Diagnosis of Pulmonary Tuberculosis 
under Programmatic Conditions in India. PLOS ONE. 2013 Oct 
9;8(10):e75566.  
56.  RICHARDS OW. The Staining of Acid-Fast Tubercle Bacteria. Am Assoc 
Adv Sci Sci. 1941 Feb 21;93(2408):190.  
57.  Brodie D, Schluger NW. The Diagnosis of Tuberculosis. Clin Chest Med. 
2005 Jun;26(2):247–71.  
58.  Jorgensen JH, Carroll KC, Pfaller MA. Manual of Clinical Microbiology. 
ASM Press; 2015. 2892 p.  
59.  Rodrigues C, Shenai S, Almeida D, Sadani M, Goyal N, Vadher C, et al. Use 
of bactec 460 TB system in the diagnosis of tuberculosis. Indian J Med 
Microbiol. 2007;25(1):32.  
60.  R Ramachandran. What is new in the diagnosis of tuberculosis? Part 1: 
techniques for diagnosis of tuberculosis. [Internet]. [cited 2016 May 13]. 
Available from: http://icmr.nic.in/ 
61.  WHO | Policy guidance on TB drug susceptibility testing (DST) of second-line 
drugs (SLD) [Internet]. WHO. [cited 2016 May 18]. Available from: 
http://www.who.int/tb/features_archive/xdr_mdr_policy_guidance/en/ 
62.  Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of 
results. Eur Respir J. 2005 Mar 1;25(3):564–9.  
101 
 
63.  WHO | Companion handbook to the WHO guidelines for the programmatic 
management of drug-resistant tuberculosis [Internet]. WHO. [cited 2016 May 
18]. Available from: 
http://www.who.int/tb/publications/pmdt_companionhandbook/en/ 
64.  Canetti G, Froman S, Grosset J, Hauduroy P, Langerová M, Mahler HT, et al. 
Mycobacteria: laboratory methods for testing drug sensitivity and resistance. 
Bull World Health Organ. 1963;29(5):565–78.  
65.  What is new in the diagnosis of tuberculosis ? PART II Techniques for Drug 
Susceptibility Testing Indian Council of Medical Research [Internet]. [cited 
2016 May 19]. Available from: http://icmr.nic.in/ 
66.  Klingeren B van, Dessens-Kroon M, Laan T van der, Kremer K, Soolingen D 
van. Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by 
Use of a High-Throughput, Reproducible, Absolute Concentration Method. J 
Clin Microbiol. 2007 Aug 1;45(8):2662–8.  
67.  Acharya S, Ghimire P, Khadka D, Nepali S. Comparison of Proportion and 
Resistance Ratio Methods for Drug Susceptibility Testing of 
&lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Isolated from Patients 
Attending National Tuberculosis Centre, Nepal. SAARC J Tuberc Lung Dis 
HIVAIDS [Internet]. 2010 May 7 [cited 2016 May 19];5(1). Available from: 
http://www.nepjol.info/index.php/SAARCTB/article/view/3078 
68.  Parsons LM, Somoskövi Á, Gutierrez C, Lee E, Paramasivan CN, Abimiku A 
’le, et al. Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: 
Challenges and Opportunities. Clin Microbiol Rev. 2011 Apr;24(2):314–50.  
69.  Rohner P, Ninet B, Metral C, Emler S, Auckenthaler R. Evaluation of the 
MB/BacT system and comparison to the BACTEC 460 system and solid media 
for isolation of mycobacteria from clinical specimens. J Clin Microbiol. 1997 
Dec 1;35(12):3127–31.  
70.  Díaz-Infantes MS, Ruiz-Serrano MJ, Martínez-Sánchez L, Ortega A, Bouza E. 
Evaluation of the MB/BacT Mycobacterium Detection System for 
Susceptibility Testing of Mycobacterium tuberculosis. J Clin Microbiol. 2000 
May 1;38(5):1988–9.  
71.  Espasa M, Salvadó M, Vicente E, Tudó G, Alcaide F, Coll P, et al. Evaluation 
of the VersaTREK System Compared to the Bactec MGIT 960 System for 
First-Line Drug Susceptibility Testing of Mycobacterium tuberculosis. J Clin 
Microbiol. 2012 Feb 1;50(2):488–91.  
72.  Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter 
Laboratory Validation of the BACTEC MGIT 960 Technique for Testing 
Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line 
Drugs and Newer Antimicrobials. J Clin Microbiol. 2006 Mar 1;44(3):688–92.  
102 
 
73.  Growth Detection Failures by the Nonradiometric Bactec MGIT 960 
Mycobacterial Culture System [Internet]. [cited 2016 May 22]. Available 
from: http://jcm.asm.org/content/50/6/2092.short 
74.  Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current Perspectives on 
Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the 
Automated Nonradiometric Systems. J Clin Microbiol. 2006 Jan;44(1):20–8.  
75.  WHO | Noncommercial culture and drug-susceptibility testing methods for 
screening patients at risk for multidrug-resistant tuberculosis [Internet]. WHO. 
[cited 2016 May 22]. Available from: 
http://www.who.int/tb/publications/2011/mdr_tb_diagnostics_9789241501620
/en/ 
76.  Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. 
Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB. 
N Engl J Med. 2006 Oct 12;355(15):1539–50.  
77.  Michael JS, Daley P, Kalaiselvan S, Latha A, Vijayakumar J, Mathai D, et al. 
Diagnostic accuracy of the microscopic observation drug susceptibility assay: 
a pilot study from India. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung 
Dis. 2010 Apr;14(4):482–8.  
78.  Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. 
Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB. 
N Engl J Med. 2006 Oct 12;355(15):1539–50.  
79.  Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for 
the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a 
systematic review and meta-analysis. J Antimicrob Chemother. 2007 Feb 
1;59(2):175–83.  
80.  Singh S, Kumar P, Sharma S, Mumbowa F, Martin A, Durier N. Rapid 
Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: 
Standard Operating Procedure for Non-Commercial Assays: Part 3: 
Colorimetric Redox Indicator Assay v1.3.12. J Lab Physicians. 2012 
Jul;4(2):120–6.  
81.  Singh S, Kumar P, Sharma S, Mumbowa F, Martin A, Durier N. Rapid 
Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: 
Standard Operating Procedure for Non-Commercial Assays: Part 2: Nitrate 
Reductase Assay v1.3.12. J Lab Physicians. 2012 Jul;4(2):112–9.  
82.  Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, et al. 
Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic 
testing. Am J Med Sci. 2013 Feb;345(2):143–8.  
103 
 
83.  Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D’Ambrosio L, Zignol 
M, et al. Rapid molecular TB diagnosis: evidence, policy making and global 
implementation of Xpert MTB/RIF. Eur Respir J. 2013 Jul;42(1):252–71.  
84.  Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. 
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the 
Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a 
multicentre implementation study. The Lancet. 2011 May 6;377(9776):1495–
505.  
85.  Suzana S, Shalini B, Rupali P, Venkatesh K, Christopher D, Michael JS. Rapid 
diagnosis of extra pulmonary tuberculosis by automated Xpert MTB/RIF 
assay. BMC Infect Dis. 2012;12(1):1–1.  
86.  WHO | The Global Plan to Stop TB 2006–2015 [Internet]. [cited 2016 May 9]. 
Available from: 
http://www.who.int/tb/features_archive/global_plan_to_stop_tb/en/ 
87.  Organization WH, others. The use of molecular line probe assay for the 
detection of resistance to second-line anti-tuberculosis drugs: expert group 
meeting report, Geneva, February 2013. 2013 [cited 2016 May 24]; Available 
from: http://apps.who.int/iris/handle/10665/78099 
88.  Fakruddin M, Chowdhury A, Hossain MN, Mannan KS, Mazumda RM. 
Pyrosequencing-principles and applications. Int J Life Sci Pharma Res. 
2012;2:65–76.  
89.  Ajbani K, Lin S-YG, Rodrigues C, Nguyen D, Arroyo F, Kaping J, et al. 
Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant 
Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden 
Countries. Antimicrob Agents Chemother. 2015 Jan 1;59(1):414–20.  
90.  Lin S-YG, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, et al. 
Pyrosequencing for rapid detection of extensively drug-resistant 
Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin 
Microbiol. 2014 Feb;52(2):475–82.  
91.  Rizzo JM, Buck MJ. Key Principles and Clinical Applications of “Next-
Generation” DNA Sequencing. Cancer Prev Res (Phila Pa). 2012 Jul 
1;5(7):887–900.  
92.  Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. Rapid 
Detection of Rifampin Resistance in Mycobacterium tuberculosis by 
Pyrosequencing Technology. J Clin Microbiol. 2006 Jun;44(6):1925–9.  
93.  Gega A, Kozal MJ. New technology to detect low-level drug-resistant HIV 
variants. Future Virol. 2011 Jan;6(1):17–26.  
104 
 
94.  Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev 
Pharmacol Toxicol. 2005;45:529–564.  
95.  Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB 
Gene of Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates 
from India. J Clin Microbiol. 2001 Aug;39(8):2987–90.  
96.  Yue J, Shi W, Xie J, Li Y, Zeng E, Wang H. Mutations in the rpoB gene of 
multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin 
Microbiol. 2003 May;41(5):2209–12.  
97.  Palomino JC, Martin A. Drug Resistance Mechanisms in Mycobacterium 
tuberculosis. Antibiotics. 2014 Jul 2;3(3):317–40.  
98.  Hamze M, Ismail MB, Rahmo AK, Dabboussi F. Pyrosequencing for rapid 
detection of tuberculosis resistance to Rifampicin and Isoniazid in Syrian and 
Lebanese clinical isolates. Int J Mycobacteriology. 2015 Sep;4(3):228–32.  
99.  Wang S, Zhao B, Song Y, Zhou Y, Pang Y, Ou X, et al. Molecular 
characterization of the rpoB gene mutations of Mycobacterium tuberculosis 
isolated from China. J Tuberc Res. 2013;1(1):1–8.  
100.  Patra SK, Jain A, Sherwal BL, Khanna A. Rapid Detection of Mutation in 
RRDR of rpo B Gene for Rifampicin Resistance in MDR-Pulmonary 
Tuberculosis by DNA Sequencing. Indian J Clin Biochem. 2010 
Jul;25(3):315–8.  
101.  Zheng R, Zhu C, Guo Q, Qin L, Wang J, Lu J, et al. Pyrosequencing for 
rapid detection of Tuberculosis resistance in clinical isolates and Sputum 
samples from re-treatment Pulmonary Tuberculosis patients. BMC Infect Dis. 
2014 Apr 13;14(1):200.  
102.  Van Deun A, Maug AK, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. 
Rifampicin drug resistance tests for tuberculosis: challenging the gold 
standard. J Clin Microbiol. 2013;JCM–00553.  
103.  Deun AV, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, et al. 
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin 
Susceptibility Test Results. J Clin Microbiol. 2009 Nov 1;47(11):3501–6.  
104.  Engström A, Morcillo N, Imperiale B, Hoffner SE, Juréen P. Detection of 
First- and Second-Line Drug Resistance in Mycobacterium tuberculosis 
Clinical Isolates using Pyrosequencing. J Clin Microbiol. 2012 Mar 
29;JCM.06664-11.  
105.  Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, et al. Mixed 
Mycobacterium tuberculosis complex infections and false-negative results for 
105 
 
rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical 
outcomes. J Clin Microbiol. 2014 Jul;52(7):2422–9.  
106.  Bravo LTC, Tuohy MJ, Ang C, Destura RV, Mendoza M, Procop GW, et al. 
Pyrosequencing for Rapid Detection of Mycobacterium tuberculosis 
Resistance to Rifampin, Isoniazid, and Fluoroquinolones. J Clin Microbiol. 
2009 Dec 1;47(12):3985–90.  
107.  Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType 
MTBDRsl Assay for Fluoroquinolone, Amikacin-Capreomycin, and 
Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and 
Clinical Specimens. J Clin Microbiol. 2009 Jun 1;47(6):1767–72.  
108.  Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, et al. 
Frequency and Geographic Distribution of gyrA and gyrB Mutations 
Associated with Fluoroquinolone Resistance in Clinical Mycobacterium 
Tuberculosis Isolates: A Systematic Review. PLOS ONE. 2015 Mar 
27;10(3):e0120470.  
109.  Georghiou SB, Seifert M, Lin S-Y, Catanzaro D, Garfein RS, Jackson RL, et 
al. Shedding light on the performance of a pyrosequencing assay for drug-
resistant tuberculosis diagnosis. BMC Infect Dis. 2016;16:458.  
110.  Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, et al. 
Correlating rrs and eis promoter mutations in clinical isolates of 
Mycobacterium tuberculosis with phenotypic susceptibility levels to the 
second line injectables. Int J Mycobacteriology. 2016 Mar;5(1):1–6.  
111.  Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, 
Rodwell TC. Evaluation of Genetic Mutations Associated with Mycobacterium 
tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A 
Systematic Review. PLOS ONE. 2012 Mar 29;7(3):e33275.  
112.  Barnard M, Warren R, Van Pittius NG, van Helden P, Bosman M, Streicher 
E, et al. GenoType MTBDRsl Line Probe Assay Shortens Time to Diagnosis 
of Extensively Drug-Resistant Tuberculosis in a High-Throughput Diagnostic 
Laboratory. Am J Respir Crit Care Med. 2012 Dec 15;186(12):1298–305.  
113.  Ninan MM, Gowri M, Christopher DJ, Rupali P, Michael JS. The diagnostic 
utility of line probe assays for multidrug-resistant tuberculosis. Pathog Glob 
Health. 2016 Aug 8;1–6.  
114.  Nikam C, Patel R, Sadani M, Ajbani K, Kazi M, Soman R, et al. Redefining 
MTBDRplus test results: what do indeterminate results actually mean? Int J 
Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2016 Feb;20(2):154–9.  
115.  Georghiou SB, Ajbani K, Rodrigues C, Rodwell TC. Performance of a 
pyrosequencing platform in diagnosing drug-resistant extra-pulmonary 
106 
 
tuberculosis in India. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 
2016 Feb;20(2):160–5.  
116.  Huang W-L, Chen H-Y, Kuo Y-M, Jou R. Performance Assessment of the 
GenoType MTBDRplus Test and DNA Sequencing in Detection of Multidrug-
Resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009 Aug 
1;47(8):2520–4.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OFFICE OF R.ESEARCII
INSTITUTIONAL REVIEW BOARD flRB)
CHRISTIAN MEDICAL COLLEGE, VELLORE, INDIA.
Dr BJ Pnshdrnrn, M A , M.a.. D. Mi (chocd)
ch:i|F^m,Elhiscmnii@
TIIONIAS
Dr Alfred Job Droi.l, D (fu. Ms onb, NB oft
cnairpdon, Rerah Chmi@ & Principal
MD 
. 
MNAMS., DNB (Endo), .nAcp (Endot FRcp (Edii), FRcp {clas)
Addiried vn. Pft.ip3r (R6dch)
l)cr hor ofc[nic?l NlLcr nnog!
Chnsn Nlldicil Collcgc,v.ll(rc612lJol
Fluid R c6carcn Gr.nr P tojcd:
-lo erilLet rynrkquc.cnrg fd thc flpid dct.cdon of 
^ltJtidftE 
dn$
(\i{xnr i.d.xtcdirclltl{a rqsisiin!$b-."l.sis,\ Pilor studv
D! ni\hv,4.: G..1PC n-i$s@4 Di Jot sroji'ri llchrcl, (ll"!cil
\hcrobn,la4, Drjlirkh. Pm, (;cncfil,J.rxIhaIoEI, (:Il(:, \'clld./:? . ,. .. ,:. i\,.Rr !ft8 \Li No er r r ,.rr-\cNorL, . 
"ri d / r.nri
l)cr lrr. ]\ishNma. C. '. 'a
I .nclos l( tl,lli^vi'lg dqqDdna
11. r r 1. \li lr . i'i.l\' oLi l!...\r.\"1
,1rc grumrtr-,r,-,1!.o
s,,,,"- 
"\ -, b.l^.,i
Elhic comniiee Brue offce ot
Iel : 4116 - 22U291, 2244202
Re*ar.n, lsl Floor Caman Blek Ch.idian Med cal
F* : 0416, 22621AA. 22A!..a1
collese, Velloc, Tamil Nado 332 002
E{.il : B$.rch@cmddb€.ac in
OFFICE OF RESEARCH
INSTITUTIONAL RIVIEW BOARD 
'IR3)CIIRISTIAN MEDICAL COLLEGE, VELLORE, INDIA.
Di BJ }ruhc.tirn, M.A., M A., D. Mi (crbid)Ditui cbrisrim cmcrjns c.hr.r,
chd'p.cor, q{!i€ comid.c.
D. Alfr.d Job D.!iel, D o11ho. Ms onhq irNB o'rhD
o"irr.noa R*rrh Cdimi@ & Ptii.iprl
m.,MN Ms., DNts (Endol FRACP (Endol FR€P (lditrI PRCP (arsg)
Ssrcbry, Anics Cdnnide, IP.B
Addliai'i \re ftin.iplr adftD
PC R.gnnr
D.ar'iment oi clinicxl Mcrobiolo$-
Cbsnan Nledical C.[.ee, vc0or 632 004
sub, Fluid RcselrcL G@r PoicctT. MluE Prrosequo.nrs rol.$e sPd detction or Mr ddds dng
*,.,u- 
" 
d 
".ic;*:\ d,vsr.i.rri!&D.,culo h \ pro. ' rJu A' F*?rF qlils<5!6F4r, Dl J"j ''-r'' \1rh'"rjni!/rMi.-b-rd{e-lD*ikh, l]Iil c-.ai.li*dosv c^lc, v.uoren.-r,.rely,.o*r$?tr u,i d '.rri. ",$,1
, ... ,i{ 
"*:",^ 
* , t , *""4, .\l{\f,,,'m*R.r B,9 NiHN?, 9r4UL?l&G!]tYt 
- 
',/ a:, \a 
= 
i.l
"-.o. o+*"." o-vi 
** t ",: 'i 
--= 
r' i
' 
.-!, "4 I,' J f'
r r.. r-' .*--, * .* J".a*GIr.r {trxRkt;l tft'!, L"*' 'e' vr 'h' i l- b2'\l.d.r 'ou"cc. \.''.;t,!b..d 
'tld diyr-d 16'* Dior.( .'r'l'd la flrlur
'.;;;;,., i,., \",,ffd +!rm, lr\', rddde.rrs r.i.nn, :rd'r cn . ar d,'e
-.i""; tub-;,"." ,\ db':-riftjlo$Sr:bt 
'n':0,4
'.n...--"-. 
-'u]?id"ii.$i'e <ro.um.nr:
t. IRB ADDlicrtion fomzt
2. curicniuh vnxe'or Ds ,\ishw,ryr G,Joy Sarciini Nnchrel, Rckhx Pai
I lnfon.d Conscn, fom & Inaoftrtion Shcd (E.gLish, Tlnil & l 
'lwu)4. Clinisl R.sc{ch }om
'rhe foDowioe l.sritutionil R.view Boid (Blue, Rescrch & Edncs C'nmite€) ndbcF
v{. pr.s.nr fic n.ciing held on Nov€mbcr 12h 2014 in rhc CIIEST /SACN Conferenc'
R@m. CMsLir. Nlediol CoD.s., Brs41h. Velor. 632002
Elhi6 Comn fee Blue, Off@ ol Reeadl
Ll: c,416 - 2234294,22UX2
lst Fle( Caman Blct, Chlbtj.n M€di€l
Fd: 0n16 - Ua2laa, z2u1A1
correg., V.rroc, Tanit Nadu 632 C92.
E{6il : Es@rch@dddbB .c.in
OFFICE OF R.ESEARCIT
INSTITUTIONAL R.EVIEW BOARD gRB)
CIIRISTIAN MEDICAL COLLEGE, \'ELLORE, INDIA.
Di B.J. P@tu.hcD, M 
^ 
, M a, Di Mh (c1hi.r)
cr.nr.6oa qli6 connin ..
Di Alfred Job D.lig| D oe, M eb, DNB tu
Chria.ls, Redch comni@ & Pitrcip,l
MD., wAMs , DM (Eidd), FMCP (bdo), rRcP ([din), FRCP (a|ae)
s@ory, Erhi6 Comni@, m!
Additienrl M€ Pntrcid (a!sch)
IJBBS,TID.DNJ
,iir'S 
.
''t ) .. I
,= 
-.:
..0rR'-,SciiV'
.fil,,ud vitQ1os",Jl!!-S!qJ]-
MBBinitr:--:.
IRB rh. Noi 9131 [DIA(;N()SL] dltcd 12112014
E$ 6 Comm'tee B ue, offc€ ot
re u1a - 22412u,22u202
Rs$*dr, 1st Fl@r, Cadan Blet, Chdstian
F d : 0416 - 22821Aa, 22U4A1
Medl@l Collese, Vellorc Tahil N adu 632 002
E{.il : B$EEh@nddoE .c.in
{ffi: OFFICE OF RESEARCIIINSTITUTIONAL REVIEW BOAF.D OR3)CIIRISTIA\ MEDICAL COLLECE, VELLOR-8, INDIA.
Dn &J, Prbrbrhrd,M.A.MA. Dt Mdi.ihrr)
chairyeBd, {lr'ics connre
DrAlfed JobDrbiel.Dodh Msonh. DNBoiio
chiipa.on. R6.rch Cmmi@& Eiicipal
MD , MNAMS . DNB (Enlo), FRACP (Endol FRCP (Edir), rRcP (aLq)
Addhioid vk. Pii.ipal(Rs.r.h)
4ql!!ll
I"c!l llr!!!!
'| J) 121:1IlL
tRFN L ! rrr! r)r\(. rr\ lJicJlzlll0lr
Cnt(;, \'.llo'9_
EihicsCommieeSlue Ofca ol Reearch,
ht : 4116 2231294, 2234202
lslFlooiCamai Block ChistsnMedi€l co €95, v.nore, Iam Nadu 632 002E{a rcsearch@mwe lore.a in
ffi OFFICE OF R.ESEARCHINSTITUTIONAL REVIEW BOARD (IRB)CHRISTIAN MEDICAL COLLEGE, VELLORE, INDIA.
M'A,. ft Mi i.lncD
cMiDc6o4 E!'ns comm'ne.
t'
Di Alrred Job Dlbiel,Doih. Ms onho, DNB otu
MD 
. 
maMs 
. 
DNB (Eodd, FR^.P (ErdO. FR.P (Edo), FR.P (crde)
Addi'ional vi.. Primipal (Rsddt
t rmi,r ). rRrl
\. {{,' , 
'r r.r*1.'. ,luu.li lr('dn.n
Ithi.: Con'nn( cxn.d3 t. b. mi,"ndL rb"!r rl( Progic'r or 
'r'rJtcF.ctenbo L'iA1 l u'o' nP 
'
Doio."r rnd (hc n,ucd inromr"on / intamed .unscu' '
''' ! |nnrlrePnl "- L
,.1. dr /r ..Lr!rr,-&ji r!| I r\r'
liriod md o e Crl(- {cbnic link aad(s: hrtDi/rN\sv'md)
!l!a!q!!!iti cc{.h/hr!.\'hhl
ltr, lr L!!t!!!!lL t\t' r,1aL\')LL!l\)!!1) t/.!: = r rall1llll IIl!nl
r.tulA! t r)utu't arir L
txtl t11rta. t tllLLD@r
'iX:ffi#ii,;:ffifr;if
L ri! b nhr{t tt t!/t!!al1L l44@a+tup,4!"@
li t/'
[''
-tIJI NI'IAI, TIIOIIAS
./
I h l\ IRL.
i\li.hx.l, (ll'oni'l rlidlLnlng,. (l\l(i. \.1 o(
ll)r \(;N()s| dr(l il l1r1rl.1
EihicsComnfieeSlue Otre ol Resarch,
ret: a416 - 22U2s4,2234202
1sl Floo, Camai Block. Christan Medial
Fax 0415 - 226273a,22u4s1
co ege,Veno€, Tam N5du632 oo2.E{ai €earch@dde deacin
ISOLATE NO. STATE AGE SEX RIF (LJ DST) OFLOX (LJ DST) CAP (LJ DST) KAN  (LJ DST) Gene Xpert PYRO rpoB PYRO gyrA PYRO rrs PYRO eis
ISO 1 West Bengal 27 M R R S S RESISTANT GAC516GTC GAC94CAC WT
ISO 2 Tamil Nadu 21 M R S S S RESISTANT TCG531TTG WT WT WT
ISO 3 West Bengal 15 F R R S S RESISTANT TCG531TTG GAC94GGC WT
ISO 4 West Bengal 33 M R R S R RESISTANT TCG531TTG GAC94AAC WT WT
ISO 5 Jharkhand 16 M R R S S RESISTANT TCG531TTG GCG90GTG WT
ISO 6 West Bengal 44 M R S S S RESISTANT FAIL WT WT
ISO 7 Sikkim 23 M R R S S RESISTANT TCG531TTG GAC94GCC WT
ISO 8 Assam 25 M R R S S RESISTANT TCG531TTG GAC94GGC WT
ISO 9 Bihar 25 F R R R R RESISTANT GAC516GTC GAC94GGC WT WT
ISO 10 Jharkhand 44 M R S S S RESISTANT TCG531TTG WT WT WT
ISO 11 Jharkhand 21 M R R S S RESISTANT TCG531TTG GAC94GGC WT
ISO 12 West Bengal 19 F R R R S RESISTANT TCG531TTG GAC94GGC WT
ISO 13 Tamil Nadu 46 M S S S S SUSCEPTIBLE WT WT WT
ISO 14 West Bengal 54 M R RESISTANT TCG531TTG NOT DONE NOT DONE
ISO 15 Jharkhand 18 M S S S S SUSCEPTIBLE WT FAIL WT
ISO 16 Jharkhand 22 M S S S S SUSCEPTIBLE WT WT WT
ISO 17 West Bengal 34 F S S S S SUSCEPTIBLE WT WT WT
ISO 18 West Bengal 25 M R R S S RESISTANT TCG531TTG GAC94GGC WT
ISO 19 Sikkim 28 F R S S S RESISTANT TCG531TTG WT WT
ISO 20 Jharkhand 14 F S S S S SUSCEPTIBLE WT WT FAIL
ISO 21 Tamil Nadu 34 F R S S S RESISTANT GAC516TAC WT FAIL
ISO 22 H37RA S S S S SUSCEPTIBLE WT WT WT WT
ISO 23 West Bengal 57 M R S S S RESISTANT TCG531TTG WT WT
ISO 24 West Bengal 40 M S SUSCEPTIBLE WT NOT DONE NOT DONE
ISO 25 Jharkhand 23 M R R S S RESISTANT TCG531TTG GCG90GTG WT
ISO 26 Andra Pradesh 54 M S S S S SUSCEPTIBLE WT WT WT
ISO 27 Kerala 54 M S SUSCEPTIBLE WT NOT DONE NOT DONE
ISO 28 Tamil Nadu 54 M S SUSCEPTIBLE WT NOT DONE NOT DONE
ISO 29 Bihar 54 M R RESISTANT TCG531TTG NOT DONE NOT DONE
ISO 30 West Bengal 54 M R S S R RESISTANT CAC526CTC WT WT WT
ISO 31 West Bengal 54 M R S S S RESISTANT GAC516GTC WT WT
ISO 32 Sikkim 54 F R R R R INDETERMINATE TCG531TTG GAC94GGC WT WT
ISO 33 Jharkhand 54 F R R R R RESISTANT TCG531TTG GAC94GGC WT WT
ISO 34 Orrisa 54 M R R R R RESISTANT TCG531TTG GCG90GTG A1401G WT
ISO 35 Arunachal Pradesh 54 M R R R R RESISTANT TCG531TTG GAC94GGC A1401G WT
ISO 36 West Bengal 54 M R R R S NOT DONE FAIL GAC94GCC WT
ISO 37 Jharkhand 54 M R R R S RESISTANT TCG531TTG GAC94GGC WT
ISO 38 West Bengal 54 M R R R R NOT DONE CTG511CGG,GAC516TAC GAC94GGC WT WT
ISO 39 West Bengal 54 M R R R S RESISTANT TCG531TTG GAC94TAC WT
ISO 40 Jharkhand 54 F R R R S RESISTANT TCG531TTG FAIL WT
ISO 41 West Bengal 54 M R R R S RESISTANT TCG531TTG GAC94GGC FAIL
NOT DONE
NOT DONE
NOT DONE
NOT DONE
NOT DONE
ISO 42 (D) Tamil Nadu 54 F R             NOT DONE SUSCEPTIBLE TCG531TTG NOT DONE NOT DONE
ISO 43 (D) Bihar 54 M S R S S RESISTANT FAIL GAC94GGC FAIL
ISO 44 (D) West Bengal 54 F S S S S RESISTANT CTG511CCG WT WT
ISO 45 (D) Andra Pradesh 54 M R R S S SUSCEPTIBLE FAIL FAIL WT
ISO 46 (D) Andra Pradesh 54 F S S S S RESISTANT CTG511CCG WT WT
ISO 47 (D) Andra Pradesh 54 F S  NOT DONE RESISTANT FAIL NOT DONE NOT DONE
ISO 48 (D) Andra Pradesh 54 F S S S S RESISTANT FAIL NOT DONE NOT DONE
ISO 49 West Bengal 54 M S S S S SUSCEPTIBLE WT FAIL WT
ISO 50 Andra Pradesh 54 F R R S R RESISTANT TCG531TTG GCG90GTG WT WT
ISO 51 Bangladesh 54 M S S S S SUSCEPTIBLE WT FAIL WT
ISO 52 Tamil Nadu 54 M R S S S RESISTANT TCG531TTG WT WT
ISO 53 Bihar 54 F R R S S RESISTANT TCG531TTG GCG90GTG WT
ISO 54 Meghalaya 54 F R R S S RESISTANT TCG531TTG GAC94GGC WT
ISO 55 (D) Jharkhand 54 M S S S S RESISTANT CTG511CCG WT WT
ISO 56 Jharkhand 54 M S S S S SUSCEPTIBLE FAIL WT WT
ISO 57 West Bengal 54 M R R R R RESISTANT TCG531TTG GCG90GTG C1402T WT
ISO 58 West Bengal 54 M R R R R RESISTANT TCG531TTG FAIL A101G WT
ISO 59 Tamil Nadu 54 F R R S R RESISTANT TCG531TTG GCG90GTG WT C12T
ISO 60 Jharkhand 54 F R R R R RESISTANT TCG531TTG GCG90GTG A1401G WT
ISO 61 Bihar 54 M R R R R RESISTANT TCG531TTG GAC94GGC A1401G WT
ISO 62 West Bengal 54 M S S S S SUSCEPTIBLE WT WT WT
ISO 63 Tamil Nadu 54 M R S S S RESISTANT TCG531TTG WT WT
ISO 64 Jharkhand 54 M S S S S SUSCEPTIBLE WT WT FAIL
M: Male F: Female
LJ DST: Lowenstein-Jensen (Conventional) Drug Susceptibility Testing
R: Resistant S: Susceptible
WT: Wild Type
